SG174118A1 - Novel heterocyclic compounds for use as metap-2 inhibitors - Google Patents
Novel heterocyclic compounds for use as metap-2 inhibitors Download PDFInfo
- Publication number
- SG174118A1 SG174118A1 SG2011050564A SG2011050564A SG174118A1 SG 174118 A1 SG174118 A1 SG 174118A1 SG 2011050564 A SG2011050564 A SG 2011050564A SG 2011050564 A SG2011050564 A SG 2011050564A SG 174118 A1 SG174118 A1 SG 174118A1
- Authority
- SG
- Singapore
- Prior art keywords
- triazolo
- pyrimidin
- denotes
- ylpyrrolidin
- pyrrolidin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 10
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- -1 imidazolidiny! Chemical group 0.000 claims description 147
- 150000001875 compounds Chemical class 0.000 claims description 133
- 150000003839 salts Chemical class 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 59
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 241000906142 Balistes polylepis Species 0.000 claims description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 239000004305 biphenyl Substances 0.000 claims description 9
- 235000010290 biphenyl Nutrition 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 7
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 7
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 claims description 7
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- POFDSYGXHVPQNX-UHFFFAOYSA-N triazolo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=CN=NN21 POFDSYGXHVPQNX-UHFFFAOYSA-N 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 5
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 5
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 5
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 239000003558 transferase inhibitor Substances 0.000 claims description 3
- GIAZHSRKWYDANE-UHFFFAOYSA-N 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine Chemical compound C1COCCN1C1=NC=NC2=C1C=CN2 GIAZHSRKWYDANE-UHFFFAOYSA-N 0.000 claims description 2
- TVUJWOBSYFELHX-UHFFFAOYSA-N 7-[2-(naphthalen-1-yloxymethyl)imidazol-1-yl]-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound C1=NC2=NC=NN2C(N2C=CN=C2COC=2C3=CC=CC=C3C=CC=2)=C1 TVUJWOBSYFELHX-UHFFFAOYSA-N 0.000 claims description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 102100037106 Merlin Human genes 0.000 claims 2
- 229940123468 Transferase inhibitor Drugs 0.000 claims 2
- WXBZWVAQKYYHJZ-MRXNPFEDSA-N 2-amino-1-[8-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]-3,4-dihydro-1h-isoquinolin-2-yl]ethanone Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C=CC=C3CCN(CC3=2)C(=O)CN)=C1 WXBZWVAQKYYHJZ-MRXNPFEDSA-N 0.000 claims 1
- RYLZWFXVNAEBJE-LJQANCHMSA-N 4-[8-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]-3,4-dihydro-1h-isoquinolin-2-yl]butan-1-amine Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C=CC=C3CCN(CC3=2)CCCCN)=C1 RYLZWFXVNAEBJE-LJQANCHMSA-N 0.000 claims 1
- SVFYXWXISZCPSD-CQSZACIVSA-N 4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C3=CC=CC=C3N=CC=2)=C1 SVFYXWXISZCPSD-CQSZACIVSA-N 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- MYZHMIOKPHAIDW-OAHLLOKOSA-N 7-[(2r)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C3=CC=CC=C3C=CC=2)=N1 MYZHMIOKPHAIDW-OAHLLOKOSA-N 0.000 claims 1
- PLSHYODTKUHZGO-OAHLLOKOSA-N 7-[(2r)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine Chemical compound C1=CC=C2C(OC[C@H]3CCCN3C3=CC=NC4=NC(=NN43)N)=CC=CC2=C1 PLSHYODTKUHZGO-OAHLLOKOSA-N 0.000 claims 1
- IYIVSVCRDGHFCS-OAHLLOKOSA-N 7-[(2r)-2-[[3-(trifluoromethyl)phenyl]methoxymethyl]pyrrolidin-1-yl]-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound FC(F)(F)C1=CC=CC(COC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C1 IYIVSVCRDGHFCS-OAHLLOKOSA-N 0.000 claims 1
- WQZCQODUZWAJHW-CQSZACIVSA-N C(C1=CC=CC=C1)(=O)OC[C@@H]1N(CCC1)C1=CC=NC=2N1N=CN2 Chemical compound C(C1=CC=CC=C1)(=O)OC[C@@H]1N(CCC1)C1=CC=NC=2N1N=CN2 WQZCQODUZWAJHW-CQSZACIVSA-N 0.000 claims 1
- GNVNPSPWJKLVBN-OAHLLOKOSA-N ClCc1cccc(c1)C(=O)OC[C@H]1CCCN1c1ccnc2ncnn12 Chemical compound ClCc1cccc(c1)C(=O)OC[C@H]1CCCN1c1ccnc2ncnn12 GNVNPSPWJKLVBN-OAHLLOKOSA-N 0.000 claims 1
- WECCAXFJXHMLME-GFCCVEGCSA-N IC1=C(C(=O)OC[C@@H]2N(CCC2)C2=CC=NC=3N2N=CN=3)C=CC=C1 Chemical compound IC1=C(C(=O)OC[C@@H]2N(CCC2)C2=CC=NC=3N2N=CN=3)C=CC=C1 WECCAXFJXHMLME-GFCCVEGCSA-N 0.000 claims 1
- YNBADRVTZLEFNH-UHFFFAOYSA-N Methyl nicotinate Natural products COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims 1
- FKMLLPQNBBVBHH-OAHLLOKOSA-N O=C(OC[C@H]1CCCN1c1ccnc2ncnn12)c1cccc(c1)C#N Chemical compound O=C(OC[C@H]1CCCN1c1ccnc2ncnn12)c1cccc(c1)C#N FKMLLPQNBBVBHH-OAHLLOKOSA-N 0.000 claims 1
- XRSHBBXRIOKTHM-MRVPVSSYSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methanol Chemical compound OC[C@H]1CCCN1C1=CC=NC2=NC=NN12 XRSHBBXRIOKTHM-MRVPVSSYSA-N 0.000 claims 1
- KCHHTECKVPZEQV-MRXNPFEDSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl 3-(dimethylamino)benzoate Chemical compound CN(C)C1=CC=CC(C(=O)OC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C1 KCHHTECKVPZEQV-MRXNPFEDSA-N 0.000 claims 1
- RHFTUWNNNRFJIS-CQSZACIVSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl 3-bromobenzoate Chemical compound BrC1=CC=CC(C(=O)OC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C1 RHFTUWNNNRFJIS-CQSZACIVSA-N 0.000 claims 1
- AXXDNQPYXMFULI-CQSZACIVSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl 3-fluorobenzoate Chemical compound FC1=CC=CC(C(=O)OC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C1 AXXDNQPYXMFULI-CQSZACIVSA-N 0.000 claims 1
- AJTZMZZEQDQCMQ-GFCCVEGCSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl 6-chloropyridine-3-carboxylate Chemical compound C1=NC(Cl)=CC=C1C(=O)OC[C@@H]1N(C=2N3N=CN=C3N=CC=2)CCC1 AJTZMZZEQDQCMQ-GFCCVEGCSA-N 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- INSWZAQOISIYDT-UHFFFAOYSA-N imidazo[1,2-a]pyrimidine Chemical compound C1=CC=NC2=NC=CN21 INSWZAQOISIYDT-UHFFFAOYSA-N 0.000 claims 1
- CUAUQBKUHAZSIJ-UHFFFAOYSA-N isoindole-1,3-dione Chemical compound C1=C=C[C]2C(=O)NC(=O)C2=C1 CUAUQBKUHAZSIJ-UHFFFAOYSA-N 0.000 claims 1
- IFLQNIVRGRISMD-UHFFFAOYSA-N methyl 3-ethoxybenzoate Chemical compound CCOC1=CC=CC(C(=O)OC)=C1 IFLQNIVRGRISMD-UHFFFAOYSA-N 0.000 claims 1
- 229960001238 methylnicotinate Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- AOSRCWAECNJOCO-OAQYLSRUSA-N n-[2-(1h-indol-3-yl)ethyl]-4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(NCCC=3C4=CC=CC=C4NC=3)=O)=CC(OC[C@@H]3N(CCC3)C=3N4N=CN=C4N=CC=3)=C21 AOSRCWAECNJOCO-OAQYLSRUSA-N 0.000 claims 1
- FGJJNYOJYMLOCK-LJQANCHMSA-N n-[3-(2-oxopyrrolidin-1-yl)propyl]-4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline-2-carboxamide Chemical compound C=1C(OC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C2C=CC=CC2=NC=1C(=O)NCCCN1CCCC1=O FGJJNYOJYMLOCK-LJQANCHMSA-N 0.000 claims 1
- CZAGQKHSOBMBIQ-OAHLLOKOSA-N n-ethyl-4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)NCC)=CC(OC[C@@H]3N(CCC3)C=3N4N=CN=C4N=CC=3)=C21 CZAGQKHSOBMBIQ-OAHLLOKOSA-N 0.000 claims 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 1
- OHIDOYVJPZRAHI-UHFFFAOYSA-N pentanenitrile Chemical compound CC[CH]CC#N OHIDOYVJPZRAHI-UHFFFAOYSA-N 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 description 55
- 235000002639 sodium chloride Nutrition 0.000 description 53
- 239000004480 active ingredient Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 201000010099 disease Diseases 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000012453 solvate Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 229940043237 diethanolamine Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- XSTHGTZGMYLLAN-CYBMUJFWSA-N (2r)-2-(naphthalen-1-yloxymethyl)pyrrolidine Chemical compound C=1C=CC2=CC=CC=C2C=1OC[C@H]1CCCN1 XSTHGTZGMYLLAN-CYBMUJFWSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- ODSXDBSWFKRNQN-OAHLLOKOSA-N 2-chloro-4-[(2r)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yl]pyrimidine Chemical compound ClC1=NC=CC(N2[C@H](CCC2)COC=2C3=CC=CC=C3C=CC=2)=N1 ODSXDBSWFKRNQN-OAHLLOKOSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- LLQWUYRNYQZFHK-UHFFFAOYSA-N 7-chloro-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound ClC1=CC=NC2=NC=NN12 LLQWUYRNYQZFHK-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010065630 Iris neovascularisation Diseases 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- AHZNUGRZHMZGFL-GUBZILKMSA-N Met-Arg-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCNC(N)=N AHZNUGRZHMZGFL-GUBZILKMSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- CYESCLHCWJKRKM-UHFFFAOYSA-N diuron-desdimethyl Chemical compound NC(=O)NC1=CC=C(Cl)C(Cl)=C1 CYESCLHCWJKRKM-UHFFFAOYSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229940012017 ethylenediamine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 201000008979 rubeosis iridis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- ZKSNZYLCOXUJIR-VOKUKXJJSA-N (5s,5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7-(dimethylamino)-8-hydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)N(C)C)[C@@H]3[C@@H]2C(OC3)=O)=C1 ZKSNZYLCOXUJIR-VOKUKXJJSA-N 0.000 description 1
- DLROLUIVVKTFPW-LVEBQJTPSA-N (5s,5as,8ar,9r)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](NC=3C=CC(=CC=3)[N+]([O-])=O)[C@@H]3[C@@H]2C(OC3)=O)=C1 DLROLUIVVKTFPW-LVEBQJTPSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- OPBPMGYBSDKJBT-DQHLZUIQSA-N (7s,9r,10r)-9-ethyl-4,6,9,10,11-pentahydroxy-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@]([C@@H](C3=C(O)C=4C(=O)C5=CC=CC(O)=C5C(=O)C=4C(O)=C32)O)(O)CC)CCOCC1 OPBPMGYBSDKJBT-DQHLZUIQSA-N 0.000 description 1
- BSRQHWFOFMAZRL-BODGVHBXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C BSRQHWFOFMAZRL-BODGVHBXSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- MZNMZWZGUGFQJP-UHFFFAOYSA-N 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCCCCCCC(O)CNCCCCCCCCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MZNMZWZGUGFQJP-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 1
- XDFCNHZKZVKIDN-UHFFFAOYSA-N 2-(naphthalen-1-yloxymethyl)-1h-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1OCC1=NC=CN1 XDFCNHZKZVKIDN-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- QUNOQBDEVTWCTA-UHFFFAOYSA-N 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)N(CCNCCCNCCN2C(C=3C=CC=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=CC=CC3=C1 QUNOQBDEVTWCTA-UHFFFAOYSA-N 0.000 description 1
- CMAZFWICMHRWOG-GFCCVEGCSA-N 2-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@@H]1N(C=2N3N=CN=C3N=CC=2)CCC1 CMAZFWICMHRWOG-GFCCVEGCSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- CURYRIVJTBNEGU-UHFFFAOYSA-L 3-bromo-1-[12-(3-bromopropanoyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5^{9}.2^{6}]hexadecan-3-yl]propan-1-one;dichloride Chemical compound [Cl-].[Cl-].C1CN(C(=O)CCBr)CC[N+]21CC[N+]1(CCN(CC1)C(=O)CCBr)CC2 CURYRIVJTBNEGU-UHFFFAOYSA-L 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- DTFQMPQJMDEWKJ-UHFFFAOYSA-N 3-ethoxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1 DTFQMPQJMDEWKJ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UVAXZJAUWXZJAT-CQSZACIVSA-N 4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]-6-(trifluoromethyl)quinoline Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC2=CC=NC3=CC=C(C=C32)C(F)(F)F)=C1 UVAXZJAUWXZJAT-CQSZACIVSA-N 0.000 description 1
- GFFXZLZWLOBBLO-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=CF)[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-BWVDBABLSA-N 0.000 description 1
- PULHLIOPJXPGJN-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 PULHLIOPJXPGJN-BWVDBABLSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- UCCCEISNAUTIDA-OAHLLOKOSA-N 5-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]isoquinoline Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C3=CC=NC=C3C=CC=2)=C1 UCCCEISNAUTIDA-OAHLLOKOSA-N 0.000 description 1
- AOWJTPJEMSFDTM-CQSZACIVSA-N 5-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C3=CC=CN=C3C=CC=2)=C1 AOWJTPJEMSFDTM-CQSZACIVSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- GBOQUHPYCRYKGV-UHFFFAOYSA-N 5-nitro-2-(2-pyrrolidin-1-ylethyl)benzo[de]isoquinoline-1,3-dione Chemical compound O=C1C(C=23)=CC=CC3=CC([N+](=O)[O-])=CC=2C(=O)N1CCN1CCCC1 GBOQUHPYCRYKGV-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- KAEVHZSIYLATMK-UHFFFAOYSA-N 6-n-[bis(aziridin-1-yl)phosphoryl]-2-n,2-n,7-trimethylpurine-2,6-diamine Chemical compound C=12N(C)C=NC2=NC(N(C)C)=NC=1NP(=O)(N1CC1)N1CC1 KAEVHZSIYLATMK-UHFFFAOYSA-N 0.000 description 1
- RGVRUQHYQSORBY-UHFFFAOYSA-N 7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(CCO)CC1OC1CC(N)C(O)C(C)O1 RGVRUQHYQSORBY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- BCTCNJXSYRAZDU-MRXNPFEDSA-N 7-[(2r)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]triazolo[1,5-a]pyrimidine Chemical compound C1=NC2=NC=NN2C(N2CCC[C@@H]2COC=2C3=CC=CC=C3C=CC=2)=C1 BCTCNJXSYRAZDU-MRXNPFEDSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000020119 Caplan syndrome Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012646 Diabetic blindness Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- RSCIYYHIBVZXDI-UHFFFAOYSA-O Fagaridine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(O)=C4C=[N+](C)C3=C21 RSCIYYHIBVZXDI-UHFFFAOYSA-O 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 1
- 101710169152 L-amino oxidase Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038546 Renal vasculitis Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000112708 Vates Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000029770 Wissler syndrome Diseases 0.000 description 1
- 208000016087 Wissler-Fanconi syndrome Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- BWMJVNFFFGOBGM-SECBINFHSA-N [(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OC[C@H]1CCCN1C1=CC=NC2=NC=NN12 BWMJVNFFFGOBGM-SECBINFHSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- OBNUFUMPYHEQQP-UHFFFAOYSA-N [1-(oxolan-2-yl)imidazol-2-yl]methanol Chemical compound OCC1=NC=CN1C1OCCC1 OBNUFUMPYHEQQP-UHFFFAOYSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2s,4s)-4-[(2r,3r,4r,5s,6s)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 229950005033 alanosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229950001104 anhydrovinblastine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- GMJWGJSDPOAZTP-MIDYMNAOSA-N bms-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106135 cellulose Drugs 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 229950009017 cemadotin Drugs 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- POADTFBBIXOWFJ-VWLOTQADSA-N cositecan Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229950007457 dibrospidium chloride Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950004438 elinafide Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229950011325 galarubicin Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229950005254 irofulven Drugs 0.000 description 1
- NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229940006116 lithium hydroxide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GBWHKZLQISMBOD-UHFFFAOYSA-N methyl 2-[[1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methyl]-1h-indole-5-carboxylate Chemical compound C1=NC2=NC=NN2C(N2CCCC2CC=2NC3=CC=C(C=C3C=2)C(=O)OC)=C1 GBWHKZLQISMBOD-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical group CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- IPTCQKYDTPVBGM-HXUWFJFHSA-N n-benzyl-4-[[(2r)-1-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-2-yl]methoxy]quinoline-2-carboxamide Chemical compound C=1C(OC[C@@H]2N(CCC2)C=2N3N=CN=C3N=CC=2)=C2C=CC=CC2=NC=1C(=O)NCC1=CC=CC=C1 IPTCQKYDTPVBGM-HXUWFJFHSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003903 oxygen Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950004317 pinafide Drugs 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229950007401 pumitepa Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- VHHXPMZWWBVLPB-UHFFFAOYSA-N pyrrolidin-2-ylmethyl 3-cyanobenzoate Chemical compound C=1C=CC(C#N)=CC=1C(=O)OCC1CCCN1 VHHXPMZWWBVLPB-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 190014017285 satra- platin Chemical compound 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000033962 signal peptide processing Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003102 tasonermin Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
: WO 2010/083870 PCT/EP2009/009218 -1-
Novel heterocyclic compounds as MetAP-2 inhibitors
The invention relates to compounds of the formula {or
R1 Y-X-R
Z in which denotes pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imida- zolyl, imidazolinyl, imidazolidinyl, 2-oxa-5-azabicyclo[2.2.1]hept- 5-yl, morpholinyl or N,
Zz denotes imidazopyrimidinyl, imidazotriazinyl, triazolopyrimidinyl, triazolotriazinyl, triazolopyridazinyl, tetrazolopyrimidinyl, tetrazolo- triazinyl, tetrazolopyridazinyl, pyrazolopyridaziny! or pyrrolo- pyrimidinyl, each of which is unsubstituted or monosubstituted by
R?, where Z is bonded to a nitrogen of the radical D,
R' denotes H, Hal, =O, OH, NH,, A or COA, ( R? denotes H, A, Hal, NH,, SCH;, OH or =0, h 25 R® denotes H or alkyl having 1-6 C atoms,
X denotes O(CHy),, NH, NA, OC(=0), NHSO; or is absent,
Y denotes CH=CH, (CH), or is absent,
R denotes H, Ar, Het or Carb’,
Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubsti- tuted or mono-, di-, tri, tetra- or pentasubstituted by Hal, A, OR® (CH2)mN(R®)2, NO2, [C(R®)2].CN, (CH2)mCOOR®, CON(R®),,
NR°COA, NR®SO,A, COR®, SO,N(RP),, S(0)qA, SO,0H,
CH=CH-CONH(CH;},0H, NHCONH-Het, NHCONHA, (CH2)mAr', O(CH2)mAI', O(CHz)mHet?, O(CH2)mCOOR?,
NHCONH-(CH.,},, LY
OHet (CHz)mHet, CHaNH[(CH2)20]q[(CH2)20]5(CH2)pNHa, 0 CH3;N(COA)CH,CH{OH)CHLOH,
CH2NH(CHa)qHet, CHoN(COA)(CHz) Het, CHzN(CHO)CHa)qHet,
COHet, NHCOCH[(CH2)mCOOAINHCOO(CH,)mAT,
NHCOCHI[(CH2)mCONH;JNHCOOA,
NHCOCHI[(CH2)mCOOH]NHCOOH, - NHCOCH[(CHz)mHet’]NHCOOA, ~ NHCOCH[(CHz)mHet’]NH,,
NHCOCH[(CH2)mCONH;]NH,, CH=CH-COOR® and/or
CH=CH-CON(R®),,
Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aro- matic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or monec-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2)mN(R®)2, NO, (CHz)mCN, (CH2)mCOOR®,
CONH(CH2)mCOOH, CONH(CHy)mHet?, CO(CH)mN(R®:,
CO(CH2)mNH(CH>),COOA, COO(CHa)mAr, (CH2),CONH(CH2)mAr', COCH[(CH2)mCONH]NHS,, - COCHI[(CH2)mCONH;]JNHCOOA, COCH[(CH2)mHet’INHCOOA,
COCH[(CHgz)mHet’ INH,
COCH[(CH2)nNHCOOAJNHCOO(CHz)mAr,
COCH[(CH2)mNH2]INHCOO(CH2) mA,
COCH(NHCOA)CH;CONH,, (CH2)NHCOOA,
COCH[(CH2)nCNINHCOOA, COO(CH2)mCN, COO(CH,)mN(R®),, and/or CO(CH2)mCON(R®),
NR®COA, NR®SO,A, COR? SO,NR®, S(0)A, NHCONH-(CHa)pm-
Cyc-OR®, CONH(CH,),0R®, O(CH,),0R®, CHO, (CHy)mHet?,
COHet?, (CH) NH(CHa)nHet, (CH2)mNH(CHaz)mAr,
NH(CH2)sN(R®)z, (CH2)mAI", O(CHy)mAr! and/or =O (carbonyl oxygen), and in which one N may also be oxidised,
Cyc denotes cycloalkylene having 3-7 C atoms,
Ar’ denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or ° pentasubstituted by Hal, A, OR®, COOR®, CON(R®),, NR®COA,
SO,NH; and/or CONH(CHg),Het?,
Carb’ denotes
R7 -€ { A : o ; o ,
O
FLL OL : ©
R® denotes OR®, COOR®, CON(R®); or Het’,
R’ denotes (CH;),CON(R®),, (CH2),CON[(CH,CH2)OH], or (CH2){CONH(CH,>CH,)OH, { : Het’ denotes imidazolyl, pyrazolyl or 4-chloro-2-methylpyrazolyl,
Het? denotes a monocyclic aromatic or saturated heterocycle having 1 to 2 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR®, NHCOA, N(R®), and/or =O {carbonyl oxygen),
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, Cl, Br and/or OH, or cyclic alkyl having 3-7 C atoms,
Hal denotes F, CI, Brorl, m denotes 0,1, 2, 3,4, 50r6,
v -4- n denotes 1 or 2, p denotes 1, 2, 3 or 4, q denotes 0, 1, 2, 3 or 4, r denotes 0, 1 or 2, ° and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
The invention was based on the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation
Oo of medicaments.
It has been found that the compounds of the formula | and salts thereof have very valuable pharmacological properties while being well tolerated.
In particular, they exhibit a regulatory, modulatory and/or inhibiting action on metal proteases, preferably on methionine aminopeptidase (MetAP), particu- larly on the sub-type MetAP-2.
They can be used as medicaments against cancer, but also as medicaments which positively influence fat metabolism, but also as medicaments against inflammation. ( - 25 Other purine derivatives for combating cancer are disclosed in WO 2007/017069.
WO 01/79157 describes substituted hydrazides and N-alkoxyamides which have MetAP-2 inhibitory activity and can be used for the inhibition of angio- genesis, in particular for the treatment of diseases, such as, for example, can- cer, whose development is dependent on angiogenesis.
WO 02/081415 describes MetAP-2 inhibitors which can be used for the treat- a5 ment of cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularisation, psoriasis, ocular neovascularisation and obesity.
WO 2008/011114 describes compounds as angiogenesis inhibitors and
MetAP-2 inhibitors which can be used for the freatment of lymphoid leukaemia and lymphoma. } oo
The action of the compounds according to the invention against cancer lies in particular in their action against angiogenesis. Angiogenesis inhibition has pro- ven helpful in more than 70 diseases, such as, for example, ovarian cancer (F. Spinella et al. J. Cardiovasc. Pharmacol. 2004, 44, 5140), breast cancer (A. Morabito et al. Crit. Rev. Oncol./Hematol. 2004, 49, 91), prostate cancer £m (B. Nicholson et al. Cancer Metastas. Rev. 2001, 20, 297), diabetic blindness, or psoriasis and macular degeneration (E. Ng et al. Can. J. Ophthalmol. 2005, 23, 3706).
Proteases regulate many different cell processes, particularly the modulation of peptides and proteins, particularly protein conversion, protein ripening and signal peptide processing, the breakdown of abnormal proteins and the deacti- vation/activation of regulatory proteins. In particular, the amino-terminal modi- fication of nascent polypeptides represents the most frequent modulation.
Aminoproteases are metalloproteases which cleave off amino acids from the unprotected N terminus of peptides or proteins, which can be carried out in « either a co- or post-translatory manner. - 25 Methionine aminopeptidase (MetAP) cleaves terminal methionine of nascent peptides in particular if the penultimate amino acid is small and uncharged (for example Gly, Ala, Ser, Thr, Val, Pro or Cys).
In many disease processes, angiogenesis is either causally at the centre of the disease or has a worsening effect on the progression of the disease. In cancer events, for example, angiogenesis results in the tumour increasing in size and being able to enter other organs. Other diseases in which angio- 3 genesis plays an important role are psoriasis, arthrosis, arteriosclerosis and eye diseases, such as diabetic retinopathy, age-induced macular degenera- tion, rubeosis iridis or neovascular glaucoma, furthermore in inflammations.
The compounds of the formula | on which this invention is based, composi- tions which comprise these compounds, and the processes described can thus be employed for the treatment of these diseases. :
Accordingly, the compounds according to the invention or a pharmaceutically acceptable salt thereof are administered for the treatment of cancer, including solid carcinomas, such as, for example, carcinomas (of the lungs, pancreas, thyroid, bladder or colon), myeloid diseases (for example myeloid leukaemia) or adenomas (for example villous colon adenoma). { Y The tumours furthermore include monocytic leukaemia, brain, urogenital, lym- phatic system, stomach, laryngeal and lung carcinoma, including lung adeno- carcinoma and small-cell lung carcinoma, pancreatic and/or breast carcinoma.
The present invention therefore relates to compounds according to the inven- tion as medicaments and/or medicament active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds accord- ing to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the said diseases and to a process for the treatment of the said diseases comprising the administration of one or more compounds according to the invention to a patient in need of such an administration.
CO
It can be shown that the compounds according to the invention have an anti- carcinogenic action. The compounds according to the invention are adminis- tered to a patient having a disease, for example to inhibit tumour growth, to reduce inflammation associated with a lymphoproliferative disease, to inhibit 20 transplant rejection or neurological damage due to tissue repair, etc. The pre- sent compounds are suitable for prophylactic or therapeutic purposes. As used herein, the term "treatment" is used to refer to both the prevention of diseases and the treatment of pre-existing conditions. The prevention of proliferation/ vitality is achieved by administration of the compounds according to the invention prior to the development of overt disease, for example for preventing x ST tumour growth. Alternatively, the compounds are used for the treatment of on- going diseases by stabilising or improving the clinical symptoms of the patient.
The host or patient can belong to any mammalian species, for example a pri- ° mate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experi- mental investigations, providing a model for treatment of a human disease.
The susceptibility of a particular cell to treatment with the compounds accord-
OS ing to the invention can be determined by in vitro testing. Typically, a culture of the cell is incubated with a compound according to the invention at various concentrations for a period of time which is sufficient to allow the active agents to induce cell death or to inhibit cell proliferation, cell vitality or migration, usu- ally between about one hour and one week. In vitro testing can be carried out using cultivated cells from a biopsy sample. The amount of cells remaining after the treatment are then determined.
The dose varies depending on the specific compound used, the specific dis- ease, the patient status, etc. A therapeutic dose is typically sufficient consid- erably to reduce the undesired cell population in the target tissue, while the viability of the patient is maintained. The treatment is generally continued until 0 a considerable reduction has occurred, for example an at least about 50% - 25 reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body.
It has been found that the compounds according to the invention cause speci- 30 fic inhibition of MetAP-2. The compounds according to the invention preferably exhibit an advantageous biological activity which can be detected in the tests described, for example, herein. In such tests, the compounds according to the invention exhibit and cause an inhibiting effect, which is usually documented by ICs values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range.
¥ -8-
In addition, the compounds according to the invention can be used to achieve additive or synergistic effects in certain existing cancer chemotherapies and radiotherapies and/or to restore the efficacy of certain existing cancer chemo- therapies and radiotherapies.
Compounds of the formula | are also taken to mean the hydrates and solvates of these compounds, furthermore pharmaceutically usable derivatives.
The invention also relates to the optically active forms (stereoisomers), salts, the enantiomers, the racemates, the diastereomers and the hydrates and sol-
Fo vates of these compounds. The term solvates of the compounds is taken to o mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvate are, for example, mono- or dihydrates or alkoxides.
The term pharmaceutically usable derivatives is taken to mean, for example, the salts of the compounds according to the invention and also so-called pro- drug compounds.
The term prodrug derivatives is taken tc mean compounds of the formula which have been modified by means of, for example, alkyl or acyl groups, sug- ars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention. ( These also include biodegradable polymer derivatives of the compounds - 25 according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995).
The expression “effective amount” denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for exam- ple, by a researcher or physician.
In addition, the expression “therapeutically effective amount” denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence:
s -0- improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side effects or also the reduction in the advance of a disease, condition or disorder.
The expression “therapeutically effective amount” also encompasses the amounts which are effective for increasing normal physiological function.
The invention also relates to the use of mixtures of the compounds of the for- mula |, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. £0 These are particularly preferably mixtures of stereoisomeric compounds.
The invention relates to the compounds of the formula | and salts thereof and to a process for the preparation of compounds of the formula | and pharma- ceutically usable salts, tautomers and stereoisomers thereof, characterised in that a compound of the formula
R' Y-X-R 1 . 5 H in which R" X,Y and R have the meanings indicated in Claim 1, 30 is reacted with a compound of the formula Ill
Z-Cl HI in which Z has the meaning indicated in Claim 1,
and/or a base or acid of the formula | is converted into one of is salts.
Above and below, the radicals R, X,Y, Z, R® and R* have the meanings indicated for the formula |, unless expressly indicated otherwise.
A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3,4, 5,6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, iso- propyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or ' . 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethyl- butyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethyl- propyl, further preferably, for example, trifluoromethyl.
A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluorcethyl or 1,1, 1-trifluoroethyl.
Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
R! preferably denotes H, A or COA, very particularly preferably H, methyl oder £0 acetyl. “25 R? preferably denotes H or NH,
R® preferably denotes H, methyl ethyl, propyl or butyl.
Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, c-, m- or p-tert-butylphenyl|, 0-, m- or p-trifluoromethylphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromo- phenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-meth- oxyphenyl, o-, m- or p-methylsulfonylphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-methylaminophenyl, o-, m- or p-dimethylamino- phenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-methylaminosulfonyl- phenyl, o-, m- or p-aminocarbonylphenyl, o-, m- or p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p- acetylphenyl, o-, m- or p-formyiphenyl, o-, m- or p-cyanophenyl, further preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromo- ° phenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, p-iodophenyl, 4-fluoro-3-chlorophenyli, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl or 2,5-dimethyl-4-chlorophenyl; furthermore naphthyl or biphenyl.
Ar furthermore preferably denotes phenyl, naphthyl! or biphenyl, each of which ¢ . is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OR?
N(R®)2, NO,, CN, COOR®, CON(R®),, NR°COA, NR®SO,A, COR®, SO,N(R®);,
S(0)4A, SO20H, CH=CH-CONH(CH.),OH, NHCONH-Het, NHCONHA, (CH2)mAr", O(CHa)mAr', O(CH2)mHet’, O(CH2)mCOOR®, wonton, ~
OHet {CH3)mHet, CHaNH[(CH3)20]4[(CH2)2014{CH2)pNH2,
CHaN(COA)CH,CH(OH)YCH,OH, CHaNH({CHa)qHet, CHaN(COA)Y (CHa) Het,
CH2N(CHO)(CHz) Het, COHet, NHCOCH[(CH2)mCOOAINHCOO(CHz)mAT,
NHCOCH[(CH2)nCONH]NHCOOA, NHCOCH[(CH2)nCOOHINHCOOH, oo NHCOCH[(CH2)nHetINHCOOA, NHCOCH[(CHa)mHet!INH, ~ 25 NHCOCH[(CH2)nCONH,]NH,, CH=CH-COOR® and/or CH=CH-CON(R®)..
Ar very particularly preferably denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A,
OR®, N(R®),, [C(R%2],CN, (CH2)mCOOR® and/or CH,NH(CHz)qHet.
Ar! preferably denotes phenyl which is unsubstituted or mono-, di- or trisub- stituted by Hal and/or SO,NHs.
X preferably denotes O(CHy),, NH, NA, OC(=0), NHSO; or is absent. 3% Y preferably denotes (CHy), or it is absent.
R preferably denotes H, Ar or Het.
Irrespective of further substitutions, Het denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, ° 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 8-pyrimidinyl, furthermore preferably 1,2,3-triazol- 1-, -4- or -5-yi, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazoi-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-, 4-, 5-, 6- or £7 7-indazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, - 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 8-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H- benzo-1,4-oxazinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6- yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.
The heterocyclic radicals may also be partially or fully hydrogenated.
Unsubstituted Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4- yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3~, -4- or -5-pyrrolyl, 2,5-di- oo hydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4- “25 imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4- pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3 4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4- pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3 4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3~, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H- benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3 4-methylene- dioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoro- methylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 8-yl, 2,3-(2-oxomethylene-
dioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, furthermore preferably 2,3-dihydrobenzofurany! or 2,3-dihydro-2-oxofuranyl.
Het furthermore preferably denotes a mono- or bicyclic saturated, unsaturated ] or aromatic heterocycle having 1 to 4 N, and/or O and/or S atoms which is un- substituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2)mN(R®),, (CH2)mCN, (CH2)nCOOR®, CONH(CH2)mCOOH, CONH(CHz)mHet?,
CO(CH2)mN(R®)2, CO(CH,)mNH(CH2),COOA, (CH2),CONH(CH2)mAr",
COCH[(CH2)mCONH,INH,, COCH[(CH2)mCONH2JNHCOOA, - COCH[(CHz)mHet)I]NHCOOA, - COCH(NHCOA)CH;CONH,, (CH2)NHCOOA, COCH[{CH2)mCNINHCOOA,
COO(CH2)mCN, COO(CH2)mN(R®),, CO(CH2)mCON(R®),, COR®, COHet?,
O(CHa)mAr! and/or =O (carbonyl oxygen),
Het particularly preferably denotes pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, indolyl, dihydroindolyl, benzofuranyl, dihydrobenzofuranyl, piperazinyl, morpholinyl, quinolinyl, isoquinolinyl, iso- indolyl, dihydroquinolinyl, dihydroisoquinolinyl, tetrahydroquinolinyl, tetrahydro- isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, purinyl, naphthyridinyl, pyrimidinyl, indazolyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, isoxazolyl, ro thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]- ? 25 pyridinyl, 1,3-benzodioxolyl or benzoxazolyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, (CH,)mOR®, (CH2)mN(R®)2, (CH2)mCN, (CH2)mCOOR®, CONH(CH,)mCOOH, CONH(CHy)mHet?, CO(CH)mN(R®),,
CO(CH2)mNH(CH,),COOA, (CH2),CONH(CH2)mAr!, COCH[(CHz)mCONH;]NH;,
COCHI[(CH2)mCONHINHCOOA, COCH[(CH2)mHet)INHCOOA,
COCH(NHCOA)CH;CONHg, (CH2)mNHCOOA, COCH[(CH3)»CNINHCOOA,
COO(CH2)mCN, COO(CHZ)mN(R®),, CO(CH2)mCON(R®),, COR® COHet?,
O(CHa)mAr" and/or =0.
Het furthermore preferably denotes a quinolinyl, isoquinolinyl, pyrazolyl or isoindolyl, each of which is mono-, di- or trisubstituted by Hal, A, (CH2)mORS,
(CH2)mN(R%)2, (CH2)mCN, (CH2)mCOOR?®, CONH(CH2)nCOOH,
CONH(CHa)mHet?, CO(CH2)mN(R®)2, CO(CH2)mNH(CH2),COOA, (CH) CONH(CH)mAr", COCH[(CH2)mCONH2INH;,
COCHI[(CH2);,y CONH2]NHCOOA, COCH[(CH2)mHet INHCOOA,
COCH(NHCOA)CH;CONH,, (CH2)nNHCOOA, COCH[(CH,)mCNINHCOOA,
COO(CH2)mCN, COO(CH2)mN(R®)z, CO(CH2)mCON(R®),, COR®, COHet?,
O(CHa)mAr' and/or =O.
Cyc preferably denotes cyclobutylene,cyclopentylene or cyclohexylene. o Het? preferably denotes furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridyi, pyrimidinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolid- inyl, azetidinyl, dihydrofuranyl or tetrahydrofuranyl, each of which is unsubsti- tuted or mono- or disubstituted by A, OR®, NHCOA and/or =O (carbonyl oxy- gen). 0 Het? particularly preferably denotes imidazolyl, indolyl, isoxazolyl, pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, benzofuranyl, isoindolyl, quinazolinyl, quinoxalinyl, pyrimidinyl, indazolyl, furyl, thienyl, pyrro- lyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo- £0 [1,2-a]pyridiny! or 1,3-benzodioxolyl. ho. 2 25
Hal preferably denotes F, Cl or Br, but also |, particularly preferably F or Cl.
The invention preferably relates to the compounds of the formula | which are indicated by the following sub-formulae la to Ik
EL R1 +X
N
N Y-X-R la N ib z z
R1 Y-X-R RI /~—\_-Y-X-R lc Id 7 Z
R? FHT R1 +5
N NH
~ ~~
N
. Z Z
RT. —N N
Y-X-R R? Y-X-R 1 7 x
I lg | Ih
Z Z
I " I
Z Z wo 25
H ik z
(>) preferably denotes pyrrolidinyl, imidazolinyl, pyrazolyl, 2-oxa-5-azabicyclo[2.2.1]Thept-5-yl, morpholinyl or N, very 5 . _. particularly preferably pyrralidinyl.
Z preferably denotes -pyrimidine -triazine -pyridazine
C 1 . Ay _ _ imidazo- J) L J J
SN ON SNC ON Na SN ~ _
ZT NTN Aa A NN = N= “r, JN | In oN N
N N N N SN N N~ ~N triazolo- - ” ~ ~
Ar PI Be SF om — — 7
SASH =n Ney Ay NN
Ro 25 T 7 ~ tetrazolo- | Ns At Ay = N « A= AN be Js MN one Je AN ~N
N N N N SN N XN”
N N
I pyrazolo- “O
SN and pyrrolopyrimidinyl, where the said radicals may be substituted by R%
Z particularly preferably denotes imidazopyrimidiny!, triazolopyrimidinyl or pyrrolopyrimidinyl, where Z is bonded to a nitrogen of the radical D.
Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another.
The compounds of the formula | may have one or more chiral centres and can therefore occur in various sterecisomeric forms. The formula | encompasses all these forms.
Accordingly, the invention relates, in particular, to the compounds of the for- mula | in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae laa to Inn, which conform to the for- mula | and in which the radicals not designated in greater detail have the meaning indicated for the formula |, but in which in laa (0) denotes pyrrolidinyl, imidazoliny!, pyrazolyl, 2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, morpholinyl or N;
Lo 25 intbb Z denotes imidazopyrimidinyl, triazolopyrimidinyl or pyrrolo- pyrimidinyl, where Z is bonded to a nitrogen of the radical D; inlecc R denotes H, Ar or Het; inldd Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted 39 by Hal, A, OR®, N(R®), [C(R®);].CN, (CHy)mCOOR® and/or
CHoNH(CHy) Het;
in lee Het denotes a mono- or bicyclic saturated, unsaturated or aro- matic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, > A, (CH2)mOR®, (CH2)mN(R®)2, (CH2)mCN, (CH2)mCOOR®,
CONH(CH2);COOH, CONH(CH,)mHet?, CO(CH2)mN(R®)2,
CO(CH2)mNH(CH2),COOCA, (CHa), CONH(CH,)mAr",
COCH[{CH2)mCONH2]NH,,
COCH[(CH2)mCONH,JNHCOOA, ~ COCH[(CHa)mHet’]NHCOOA, we COCH(NHCOA)CH;CONHy, (CH2)\NHCOOA,
COCH[(CH2)mCNIJNHCOOA, COO(CH2)mCN,
COO(CH4)mN(R®,, CO(CH2)mCON(R®),, CORE, COHet?,
O(CH2)mAr' and/or =O (carbonyl oxygen); in ff Ar’ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or SO,NH,; inlgg Het denotes pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, indolyl, dihydroindolyl, benzo- pe furanyl, dihydrobenzofuranyl, piperazinyl, morpholinyi, ~~ 25 quinolinyl, isoquinolinyl, isocindolyl, dihydroquinolinyt, dihydroisoquinolinyl, tetrahydroquinolinyl, tetrahydroiso- quinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, purinyl, naphthyridinyl, pyrimidinyl, indazolyl, furyl, thienyi, imida- zolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, friazolyl, tetra- zolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]pyridinyl, 1,3-benzodioxolyl or benzoxazolyl, each of which is unsub- stituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, 2 (CH2)mN(R®), (CH2)mCN, (CH,)mCOOR®,
CONH(CH2)mCOOH, CONH(CHy)mHet?, CO(CH2)mN(R®),,
CO(CH2)mNH(CH2),COOA, (CHa), CONH(CH,)mAr
COCH[(CH2)mCONH;]NH,
COCHI(CH2)mCONH,JNHCOOA,
COCH[(CHa)mHet’INHCOOA,
COCH(NHCOA)CH2CONHj,, (CH3),»,NHCOOA, ° COCH[(CH2)mCNINHCOOA, COO(CH,)mCN,
COO(CH2)mN(R®)2, CO(CH2)mCON(R®),, COR®, COHet?,
O(CHa)mAr' and/or =O; in [hh Het denotes quinolinyl, isoquinolinyl, pyrazoly! or iscindolyl, po each of which is mono-, di- or trisubstituted by Hal, A, ee (CH2)mOR®, (CH2)mN(R®)z, (CH2)mCN, (CH3)mCOOR?,
CONH(CH2)mCOOH, CONH(CH,)mHet?, CO(CH2)mN(R®),,
CO(CHa)mNH(CH,),COOA, (CH2),CONH(CH2)mAr",
COCH[(CH2)mCONH]NH,,
COCH[(CH2)CONH,JNHCOOA,
COCH[(CHa)mHet? INHCOOA,
COCH(NHCOA)CH,CONH,, (CH2)mNHCOOA,
COCH[(CH2}mCNJNHCOOA, COO(CH2)mCN,
COO(CH2)mN(R%)2, CO(CH)mCON(R®)2, COR®, COHet?,
O(CH2)mAr and/or =O; oy vo 25 inli A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and/or Ci; inlj R' denotes H, A or COA; inlkk R? denotes H or NH5; nll Y denotes (CHa), or is absent; in Imm X denotes O(CHy),, NH, NA, OC(=0), NHSO; or is absent;
in Inn (=) denotes pyrrolidinyl, imidazolinyl, pyrazolyl, 2-oxa-5-aza- ° bicycliof2.2.11hept-5-yl, morpholinyl or N,
Zz denotes imidazopyrimidinyl, triazolopyrimidinyl or pyrrolo- pyrimidinyl, where Z is bonded to a nitrogen of the radical D,
Y denotes (CHy), or is absent, oo X denotes O(CHy),, NH, NA, OC(=0), NHSO; or is absent, n R denotes H, A or COA,
R? denotes H or NH, 45 R denotes H, Ar or Het,
Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OR®, N(R%),, [C(R®)2J,CN, (CH2)mCOOR® and/or
CH,;NH(CH3)qHet,
Het denotes a mono- or bicyclic saturated, unsaturated or aro- matic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal,
A, (CH2)mOR®, (CH2)mN(R®)z2, (CH2)mCN, (CH2)mCOORS, “25 CONH(CH2)mCOOH, CONH(CHz)mHet?, CO(CH2)mN(R®),,
CO(CH2)mNH(CH),COOA, (CH),CONH(CHz)mAr,
COCHI[(CH2)mCONH;]NH,,
COCHI[(CH2)mCONH,JNHCOOA,
COCH[(CH,)mHet’INHCOOA,
COCH(NHCOA)}CH,CONHj3, (CH2)NHCOOA,
COCH[(CH2)mCNINHCOOA, COO(CH2)mCN,
COO(CHz)mN(R®)2, CO(CH2)mCON(R®),, COR’, COHet?,
O(CH2)mAr and/or =O (carbonyl oxygen), 39 Het? denotes imidazolyl, indolyl, isoxazolyl, pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, benzo-
furanyl, isoindolyl, quinazolinyl, quinoxalinyl, pyrimidinyl, indazolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]- pyridinyl or 1,3-benzodioxolyl, ) R® denotes H or alkyl having 1-6 C atoms,
Ar' denotes phenyl which is unsubstituted cr mono-, di- or trisubstituted by Hal and/or SO.NH,,
Hal denotes F, CI, Bror|, m denotes 0, 1, 2, 3, 4, 5 or 6, oo, n denotes 1 or 2, a q denotes 0, 1, 2, 3 or 4, r denotes 0, 1 or 2; and pharmaceutically usable salts, tautomers and sterecisomers thereof, including mixtures thereof in all ratios.
The compounds of the formula 1 and also the starting materials for their prepa- ration are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Ver- lag, Stuttgart), to be precise under reaction conditions which are known and fo suitable for the said reactions. Use can also be made here of variants known “ 25 per se which are not mentioned here in greater detail.
Compounds of the formula | can preferably be obtained by reacting com- pounds of the formula 1l with a compound of the formula IIL.
The compounds of the formula Hl and of the formula Ill are generally known. If they are novel, however, they can be prepared by methods known per se.
The reaction is carried out in an inert solvent and is generally carried out in the presence of an acid-binding agent, preferably an organic base, such as
DIPEA, triethylamine, dimethylaniline, pyridine or quinoline.
The addition of an alkali or alkaline-earth metal hydroxide, carbonate or bicar- bonate or another salt of a weak acid of the alkali or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.
Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150°, nor- mally between 40° and 130°, particularly preferably between 60° and 110°C.
Suitable inert solvents are, for example, hydrocarbons, such as hexane, £7 petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such oo as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propa- nol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol mono- methyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents. . Particular preference is given to glycol ethers, such as ethylene glycol mono- - 25 methyl ether, THF, dichloromethane and/or DMF.
Pharmaceutical salts and other forms
The said compounds according to the invention can be used in their final non- salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula | are for the most part prepared by conventional methods. If the compound of the formula | contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lith- ium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and > sodium propoxide; and various organic bases, such as piperidine, diethanol- amine and N-methylglutamine. The aluminium salts of the compounds of the formula | are likewise included. In the case of certain compounds of the for- mula |, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydro- £ gen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethane- sulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula | include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitro- £0 benzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophos- phate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydro- chloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, ise- thionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mande- late, metaphosphate, methanesuifonate, methylbenzoate, monohydrogenphos- phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phos- phonate, phthalate, but this does not represent a restriction.
Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(ill), iron(ll), lithium, mag-
nesium, manganese(llf), manganese(ll), potassium, sodium and zinc salts, but this is not intended fo represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline-earth metal salts calcium and magnesium. Salts of the com- ° pounds of the formula | which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine eo (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethyl- aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine,
N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D- glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropyl- amine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.
Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C;-Cs)alkyl halides, for
Fo example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; or 25 di(C4-Cy)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C10-C1g)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C4-Cg)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.
The above-mentioned pharmaceutical salts which are preferred include ace- tate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, 3° nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate,
-05. sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.
The acid-addition salts of basic compounds of the formula | are prepared by ° bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and iso- lating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to cer- go tain physical properties, such as solubility in polar solvents; for the purposes of ne the invention, however, the salts otherwise correspond to the respective free base forms thereof.
As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula | are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are
N,N’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethyl- enediamine, N-methyl-D-glucamine and procaine. { The base-addition salts of acidic compounds according to the invention are - 25 prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner.
The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.
If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the inven-
tion also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, diso- dium and trihydrochloride, but this is not intended to represent a restriction. 5S :
With regard to that stated above, it can be seen that the expression “pharma- ceutically acceptable salt” in the present connection is taken to mean an active ingredient which comprises a compound of the formula | in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic prop- erties on the active ingredient compared with the free form of the active ingre- i dient or any other salt form of the active ingredient used earlier. The pharma- - ceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic effi- cacy in the body.
The invention furthermore relates to medicaments comprising at least one compound of the formula | and/or pharmaceutically usable derivatives, sol- vates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants. eo
Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formula- tions can be administered in the form of dosage units which comprise a pre- determined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated 3 above, or a corresponding fraction thereof of an active ingredient. Further-
more, pharmaceutical formulations of this type can be prepared using a proc- ess which is generally known in the pharmaceutical art.
Pharmaceutical formulations can be adapted for administration via any desired ° suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or paren- teral (including subcutaneous, intramuscular, intravenous or intradermal} methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the { “ excipient(s) or adjuvant(s).
Pharmaceutical formulations adapted for oral administration can be adminis- tered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non- toxic and pharmaceutically acceptable inert excipient, such as, for example,
Fo ethanol, glycerol, water and the like. Powders are prepared by comminuting oo 25 the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.
Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium - stearate or polyethylene glycol in solid form, can be added to the powder mix- ture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, can likewise be added in order to improve the availability of the medicament after the capsule has been taken.
In addition, if desired or necessary, suitable binders, lubricants and disinte- ° grants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethyl- cellulose, polyethylene glycol, waxes, and the like. The lubricants used in
Fs these dosage forms include sodium oleate, sodium stearate, magnesium - stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gela- tine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, par- affin, an absorption accelerator, such as, for example, a quaternary salt, £m and/or an absorbent, such as, for example, bentonite, kaolin or dicalcium oo 25 phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cel- lulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape, which are broken up to form granules. The gran- ules can be lubricated by addition of stearic acid, a stearate salt, talc or mine- ral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the inven- tion can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differen- tiate between different dosage units.
Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic aicoholic vehicle. Suspensions can be formulated by dispersion of ro the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for oo example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can like- wise be added.
The dosage unit formulations for oral administration can, if desired, be encap- sulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like. oy The compounds of the formula | and salts, solvates and physiologically func- or 25 tional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for exarnple, cholesterol, stearylamine or phosphatidylcholines.
The compounds of the formula | and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal anti- bodies as individual carriers to which the compound molecules are coupled.
The compounds can also be coupled to soluble polymers as targeted medica- ment carriers. Such polymers may encompass polyvinylpyrrolidone, pyran co-
polymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethyl- aspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegrad- able polymers which are suitable for achieving controlled release of a medica- > ment, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxy- butyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyano- acrylates and crosslinked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration can be {oy administered as independent plasters for extended, close contact with the epi- dermis of the recipient. Thus, for example, the active ingredient can be deliv- ered from the plaster by iontophoresis, as described in general terms in
Pharmaceutical Research, 3(6), 318 (1986).
Pharmaceutical compounds adapted for topical administration can be formu- lated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In £0 the case of formulation to give an ointment, the active ingredient can be em- - 25 ployed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suit- able carrier, in particular an aqueous solvent. 3 Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.
Pharmaceutical formulations adapted for rectal administration can be adminis- tered in the form of suppositories or enemas.
Pharmaceutical formulations adapted for nasal administration in which the car- ° rier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier sub-
SD stance encompass active-ingredient solutions in water or oil.
Pharmaceutical formulations adapted for administration by inhalation encom- pass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.
Pharmaceutical formulations adapted for vaginal administration can be admin- istered as pessaries, tampons, creams, gels, pastes, foams or spray formula- tions.
Pharmaceutical formulations adapted for parenteral administration include
Fo aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is ren- dered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (Iyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
It goes without saying that, in addition to the above particularly mentioned con- stituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations . which are suitable for oral administration may comprise flavours.
A therapeutically effective amount of a compound of the formula | depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by ¢ 3 the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt thereof can be determined as the fraction of the effective amount of the com- pound according to the invention per se. It can be assumed that similar doses ( are suitable for the treatment of other conditions mentioned above. 05
The invention furthermore relates to medicaments comprising at least one compound of the formula | and/or pharmaceutically usable salts and stereo- isomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
The invention also relates to a set (kit) consisting of separate packs of (a) an effective amount of a compound of the formula | and/or pharmaceuti- 2 cally usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient.
The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each 0 containing an effective amount of a compound of the formula | and/or pharma- ceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.
Ld USE
The present compounds are suitable as pharmaceutical active ingredients for mammals, especially for humans, in the treatment and control of diseases.
These diseases include the proliferation of tumour cells, pathological neovas- cularisation (or angiogenesis), which promotes the growth of solid tumours, neovascularisation in the eye (diabetic retinopathy, age-induced macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like), and proliferative diseases of the mesangial cells.
The present invention encompasses the use of the compounds of the formula ‘ and/or physiologically acceptable salts and solvates thereof for the preparation oo 25 of a medicament for the treatment or prevention of tumours, tumour diseases and/or tumour metastases.
The tumour disease is preferably selected from the group tumour of the squamous epiof thelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx, of the lung, of the skin, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pan- creatic cancer, glioblastoma, breast carcinoma, acute myeloid leukaemia,
chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leu- kaemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma.
Likewise encompassed is the use of the compounds according to Claim 1 > according to the invention and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of osteoporosis, diabetes and obesity.
Likewise encompassed is the use of the compounds according to Claim 1
J according to the invention and/or physiologically acceptable salts and solvates ~ thereof for the preparation of a medicament for the treatment or prevention of a disease in which angiogenesis is involved.
A disease of this type in which angiogenesis is involved is an eye disease, such as retina vascularisation, diabetic retinopathy, age-induced macular degeneration and the like.
The angiogenic disease is preferably selected from the group diabetic retinopathy, arthritis, cancer, psoriasis, Kaposi's sarcoma, haeman- gioma, myocardial angiogenesis, atherosclerotic plaque neovascularisation, angiogenic eye diseases, choroidal neovascularisation, retrolental fibroplasia, macular degeneration, corneal transplant rejection, rubeosis iridis, neuroscular oo glaucoma, Oster Webber syndrome.
The proliferative disease of the mesangial cells is preferably selected from the group glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, throm- botic microangiopathy syndrome, transplant rejection, glomerulopathy.
The use of compounds of the formula | and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of inflammatory diseases likewise falls within the scope of the pre- sent invention. Examples of such inflammatory diseases include rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reaction and the like.
The inflammatory disease is preferably selected from the group
Inflammatory bowel disease, arthritis, atherosclersosis, asthma, allergies, inflammatory kidney diseases, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory skin diseases, pardontal diseases, psoriasis, T-cell- promoted immune disease.
The inflammatory bowel disease is preferably selected from the group {5 ulcerative colitis, Crohn's disease, non-specific colitis.
The T-cell-promoted immune disease is preferably selected from the group allergic encephalomyelitis, allergic neuritis, transplant rejection, graft-versus- host reaction, myocarditis, thyroiditis, nephritis, systemic lupus erythematosus, insulin-dependent diabetes mellitus.
The arthritis disease is preferably selected from the group rheumatoid arthritis, osteoarthritis, Caplan‘s syndrome, Felty's syndrome,
Sjogren's syndrome, spondylitis ankylosans, Still's disease, chondrocalcinosis, metabolic arthritis, rheumatic fever, Reiter's disease, Wissler's syndrome. -
BN 2° The inflammatory kidney disease is preferably selected from the group glomerulonephritis, glomerular injury, nephrotic syndrome, interstitial nephritis, lupus nephritis, Goodpasture’s syndrome, Wegener's granulomatosis, renal vasculitis, IgA nephropathy, idiopatic glomerular disease.
The inflammatory skin disease is preferably selected from the group psoriasis, atopic dermatitis, contact sensitivity, acne.
Likewise encompassed is the use of the compounds of the formula [ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a disease or condition in a mammal, in which to this method a therapeutically effective amount of a com- pound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies according to the specific dis- ° ease and can be determined by the person skilled in the art without undue effort.
The present invention also encompasses the use compounds of the formula and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of retinal vascularisation. oo Likewise encompassed is the use of the compounds of the formula | and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment and/or combating of a tumour-induced disease in a mammal, in which to this method a therapeutically effective amount of a compound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies according to the specific disease 50 and can be determined by the person skilled in the art without undue effort.
The disclosed compounds of the formula | can be administered in combination with other therapeutic agents, including anticancer agents. As used here, the € term "anticancer agent" relates to any agent which is administered to a patient - 25 with cancer for the purposes of treating the cancer.
The compounds of the formula | may also be administered together with other well-known therapeutic agents that are selected for their particular suitability for the condition being treated.
The present compounds are also suitable for combination with known anti- cancer agents. These known anti-cancer agents inciude the following: oestro- gen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein trans- ferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors,
reverse transcriptase inhibitors and further angiogenesis inhibitors. The pre- sent compounds are particularly suitable for administration at the same time as radiotherapy. "Oestrogen receptor modulators” refers to compounds which interfere with or > inhibit the binding of oestrogen to the receptor, regardless of mechanism.
Examples of oestrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulves- trant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1- piperidinyl)- ethoxy]phenyi}-2H-1-benzopyran-3-yllphenyl 2,2-dimethylpropanoate, 4,4'-
Fo dihydroxybenzophenone-2,4-dinitrophenythydrazone and SH646. .. "Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mechanism.
Examples of androgen receptor modulators include finasteride and other 5a- reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abi- raterone acetate. "Retinoid receptor modulators" refers to compounds which interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism.
Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, a-difluoromethylornithine, 11LX23-7553, trans-N-(4'-hydroxyphenyljretinamide and N-4-carboxyphenyiretinamide. ( "Cytotoxic agents” refers to compounds which result in cell death primarily } 25 through direct action on the cellular function or inhibit or interfere with cell myosis, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.
Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altret- amine, prednimustine, dibromodulgcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satra- platin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2- methylpyridine)platinum, benzylguanine, glufosfamide, GPX100,
(trans, trans, trans)bis-mu-(hexane-1,6-diamine)-mu-[diamineplatinum(ll)bis- [diamine(chloro)platinum(lt}] tetrachloride, diarisidinylspermine, arsenic tri- oxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubi- cin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, > valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10- hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulfonyldaunorubicin (see
WO 00/50032).
Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'- ( didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, ) mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vin- flunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-flucro-4-methoxyphenyl)- benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N- methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.
Topoisomerase inhibitors are, for example, topotecan, hycaptamine, irino- tecan, rubitecan, 6-ethoxypropionyl-3',4'-0O-exobenzylidenechartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kllacridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]- pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H, 15H)-dione, lurtotecan, 7-[2- (N-isopropylamino)ethyl]-(20S)camptothecin, BNP 1350, BNPI1100, BN80915, (_ 5 BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'- deoxyetoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyi- 6H-pyrido[4,3-blcarbazole-1-carboxamide, asulacrine, (5a,5aB,8aa,9b)-9-[2- [N-[2-(dimethylamino)ethyl]-N-methylaminolethyl]-5-[4-hydroxy-3,5-dimethoxy- phenyl]-5,5a,6,8,8a,9-hexchydrofuro(3',4":6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[glisoquinoline-5,10-dione, 5-(3-amino- propylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo- [4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H- thioxanthen-4-ylmethylJformamide, N-(2-(dimethylamino)ethyl)acridine-4-car-
boxamide, 6-[[2-(dimethylamino)ethyl]laminc]-3-hydroxy-7H-indeno[2, 1-c]- quinolin-7-one and dimesna. "Antiproliferative agents” include antisense RNA and DNA oligonuclectides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and anti- ° metabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raititrexed, paltitrexid, emitefur, tiazofurin, decit- abine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'- ; (3,4-dichlorophenyl)urea, N6-{4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycyl- - aminol-L-glycero-B-L-mannoheptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4- thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11- diazatetracyclo(7.4.1.0.0)tetradeca-2 4,6-trien-9-ylacetic acid ester, swainson- ine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl- 1-B-D-arabinofuranosyl cytosine and 3-aminopyridine-2-carboxaldehyde thio- semicarbazone. "Antiproliferative agents" also include monoclonal antibodies to growth factors other than those listed under "angiogenesis inhibitors", such as frastuzumab, and tumour suppressor genes, such as p53, which can be £ delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,089,134, for example).
Evidence of the action of pharmacological inhibitors on the prolifera- tion/vitality of tumour cells in vitro 1,0 Background [n the present experiment description, the inhibition of tumour cell prolifera- tion/ftumour cell vitality by active ingredients is described.
The cells are sown in a suitable cell density in microtitre plates (96-well format) and the test substances are added in the form of a concentration series. After four further days of cultivation in serum-containing medium, the tumour cell proliferation/tumour cell vitality can be determined by means of an Alamar Blue test system. 2.0 Experimental procedure 2.1 Cell culture
For example commercially available colon carcinoma cell lines, ovary cell lines, prostate cell lines or breast cell lines, eic.
The cells are cultivated in medium. At intervals of several days, the cells are
C detached from the culture dishes with the aid of trypsin solution and sown in suitable dijution in fresh medium. The cells are cultivated at 37° Celsius and 10% COs. 2.2. Sowing of the cells
A defined number of cells (for example 2000 cells) per culture/well in a vol- ume of 180 pl of culture medium are sown in microtitre plates (96 well cell- culture plates) using a multichannel pipette. The cells are subsequently cul- tivated in a CO2 incubator (37°C and 10% C02). 2.3. Addition of the test substances
SS The test substances are dissolved, for example, in DMSO and subsequently - 25 employed in corresponding concentration (if desired in a dilution series) in the cell culture medium. The dilution steps can be adapted depending on the efficiency of the active ingredients and the desired spread of the con- centrations. Cell culture medium is added to the test substances in corre- sponding concentrations. The addition of the test substances to the cells can take place on the same day as the sowing of the cells. To this end, in each case 20 pl of substance solution from the predilution plate are added to the cultures/wells. The cells are cultivated for a further 4 days at 37° Cel- sius and 10% CO..
i -41 - 2.4. Measurement of the colour reaction
In each case, 20 pl of Alamar Blue reagent are added per well, and the micro- titre plates are incubated, for example, for a further seven hours in a CO2 incubator (at 37°C and 10% CO2). The plates are measured in a reader with a fluorescence filter at a wavelength of 540 nm. The plates can be shaken gently immediately before the measurement. a 3. Evaluation
The absorbance value of the medium control (no cells and test substances used) is subtracted from all other absorbance values. The controls (cells with- out test substance) are set equal to 100 per cent, and all other absorbance values are set in relation thereto (for example in% of control):
Calculation: 100 * (value with cells and test substance — value of medium control) (value with cells - value of medium control)
Cso values (50% inhibition) are determined with the aid of statistics programs, such as, for example, RS1.
L: 25 ICso data for compounds according to the invention are shown in Table 1.
Material Order No. Manufacturer rer re At eee eee eee eee
Microtitre plates for cell culture 167008 Nunc (Nunclon Surface 96-well plate)
DMEM P04-03550 Pan Biotech 2 PBS (10x) Dulbecco 14200-067 Gibco 5 96-well plates (polypropylene) 267334 Nunc
AlamarBlue™ BUF012B Serotec
FCS 1302 Pan Biotech GmbH
Trypsin/EDTA solution 10x L 2153 Biochrom AG 75cm? culture bottles 353136 BD Falcon
A2780 93112519 ECACC
Colo205 CCL222 ATCC
MCF7 HTB22 ATCC a. PC3 CRL-1435 ATCC
Determination of the proliferation inhibition by inhibitors of methionine aminopeptidase 2 in the BrdU proliferation test (cellular assay)
The inhibition of proliferation is determined by incorporation of bromodesoxy- uridine (BrdU) into human umbilical vein endothelial cells (HUVECs, Promo-
Celi, C-12200). The HUVECs are cultivated at 37°C and 5% CO; in basal medium (PromoCell, C-22200) with supplement mix (PromoCell, C-39225).
After detachment of the cells by means of trypsin/EDTA, the number of living cells is determined, and the cells are sown in a density of 1000 cells per cavity
Co 25 in a total volume of 175 ul (cavities are coated in advance either with supple- mented culture medium for 1-2 hours at 37°C or with 1.5% gelatine for 0.5 - 2 hours at 37°C). After cultivation for 24 hours, the test substances are added in various concentrations (for example final concentrations 30 uM to 0.03 nM in 10-fold dilution steps) and a volume of 25 yl. The DMSO concentration is kept constant at 0.3%. After cultivation for a total of 48 or 72 hours, 20 ul of bromo- desoxyuridine (Roche, # 11647229001 diluted 1:1000 in culture medium, final concentration 10uM) are added, and cultivation is continued for a further 20 to 24 hours. After incubation with test substances for a total of 72 or 96 hours, the culture medium is removed, and an immunohistochemical determination is carried out for detection of BrdU incorporation (BrdU ELISA, Roche, #
11647229001). To this end, the cells are treated with a fixative for 30 min at room temperature and subsequently incubated with a peroxidase-labelled anti-BrdU antibody (diluted 1:100 in antibody dilution buffer) for 60 min at room temperature. After washing three times with 1-fold-concentrated DPBS > buffer (Gibco, # 14200), the enzymatic reaction is initiated in TMB substrate solution. The colour development is stopped after 15 min by addition of 25 pl of a 1M sulfuric acid solution. A determination of the optical density is carried out within 5 min by measurement at a wavelength of 450 nM. The controls used are cavities containing DMSO-treated cells (100% control) or empty — cavities (blank value). The sensitivity of this test to inhibitors of methionine aminopeptidase is checked and confirmed using the inhibitor fumagillin.
MetAP-2 activity measurement
The MetAP-2 activity is determined by coupling enzymatic reactions. The tripeptide Met-Arg-Ser (MAS) is employed as substrate. The methionine libera- 26 ted is firstly converted into Met, and HO; by L-aminooxidase (AAO). In the second step, the peroxidase (POD) with the aid of the HO, catalyses the oxi- dation of the leukodye dianisidine to dianisidineyy, the increase of which is detected photometrically at 450 nm. , MetAP-2 activity can be recorded continuously as kinetics. The reaction = 25 scheme illustrates that one mol of dianisidine,y is formed per mol of methio- nene. The MetAP-2 enzyme activity can therefore be calculated directly as A absorption per time unit. Qualification of the MetAP-2 activity (mol of Met/time unit) is possible with the aid of the dianisidiney extinction coefficient.
The change in extinction per time unit is depicted graphically and a slope cal- culation is carried out in the visually linear region of the reaction.
The activities of the compounds are summarised in Table 1.
Solubility measurement
Determination by shake flask solubility measurement : Eluent preparation:
Eluent A: 2 ml of diethylamine, for synthesis + 1000 ml of methanol, LiChrosolv . Eluent B: 5 g of ammonium acetate, for analysis +
Lo 5 ml of methanal, LiChrosolv + 995 ml of ultrapure water
Sample solvent:
Buffer: 3.954 g of sodium dihydrogenphosphate monohydrate + 6.024 g of sodium chloride + 950 ml of ultrapure water the pH is adjusted using 0.1 M
NaOH or 0.1 M HCI,
Sample preparation:
The samples are shaken at 37°C and 450 rpm for 24 h.
After about 7h, the pH of the samples is checked and adjusted if necessary. - 25
It is also checked whether the sample is still present in excess.
Just before the end of the 24h shaking time, the samples are again checked for pH and a precipitate.
Ultrapure water unit: MilliQ gradient, Millipore, instrument: F3PN37462D
Shaker: TiMix control, Blhler
Incubation hood: TH 15 Bilhler pH meter: 766 Calimatic Knick instrument: pH 1
. -45 = pH electrode: InLab 423 Mettler
APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)",
The substances are generally characterised by HPLC-MS. The column used and the gradient is indicated here. The reported retention time relates to the
MS spur (retention in the UV or ELSD spur may differ in the third decimal place). . HPLC: Column: Chromolite Performance RP18-e 50-4.6mm
Gradient: ACN/HO comprising 0.04/0.05% of formic acid
Method: polar Chromolith/Chromolith (extended)
Flow rate: 2.4ml/min [M+H]
Agilent apparatus
Chromolite Performance RIP18-e 50-4. 6mm
Gradient: ACN/H20 comprising 0.04/0.05% of formic acid
Method: polar
Flow rate: 2.4ml/min “os
The NMR spectra are recorded in DMSO-dg and in DMSO-dg + TFA-d¢. The data indicated relate to the DMSO-d spectra.
Above and below, all temperatures are indicated in °C. In the following exam- ples, "conventional work-up" means: water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the consti- tution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation.
M.p. : melting point
Mass spectrometry (MS): El (electron impact ionisation) M”
FAB (fast atom bombardment) (M+H)"
ESI (electrospray ionisation) (M+H)*
APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)".
Synthesis schemes for the preparation of some compounds according to the invention: 0
N
= NM © sy {Mo 0 —
H
{ M. OH { MO \ OH cl N N T 0 NY Or Or OO a — % en rere + [) yO) {ON {0 ZN
Fn
TL, ory
NTN
OH
+ { )., OH { JM. _o0
OH cl N - N iD
NT o> e @ o> \ NT NTN No NTN oH AY LY 9D ID { 3. 0 yO) WS Yt Pr ol C 0 o> - N - SN = TNR = | — N
Cr Po i. NP
Ne NH,
N N N N
IN on — = dN on UN a [No
Go m=
H
¢ © ¢ 9 1 ?
N N
N / \. oH / \. oo cl L Son LS “ {JS “ TJ
FI H wl 8 or or " —_— N M—— N
Ny J) Xy py xy Py
Example 1
The preparation of 7-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yl}-[1,2,4]- triazolo[1,5-a]pyrimidine ("A1"} is carried out analogously to the following scheme oom 3S yy
N N OH cr N NO S “N ~N “a N- pa ¢ AL — Sry ¢ r 1
N™ “NH, NTN NN Che @ 250 ml of conc. sulfuric acid are cooled to 0°C, and 90 g of racemic malic acid are added at such a rate that the temperature does not exceed 10°C. 54 g of 3-amino-[1,2,4]triazole are subsequently introduced in an analogous manner.
After 12 h at RT, the suspension is warmed at 100°C for one hour, giving a clear solution.
For work-up, the reaction solution is allowed to cool to RT, and the batch is poured into 300 ml of ice-water. A pH of 6 is set using concentrated NaOH > solution. The crystals which deposit in the process are filtered off with suction, washed with water and dried to constant weight in vacuo at 100°C. The prod- uct [1,2,4]triazolof1,5-a]pyrimidin-7-ol obtained melts at 290°C; HPLC: 0.475 min; MS: [273.1] (Yasuo Makisumi, Hideo Kano Bull Soc. Chem. Japan 1959, 8, 907; m.p. 286 £7 — 287°C). 2.4 g of [1,2 4]triazolo[1,5-a]pyrimidin-7-ol from the first synthesis step are introduced into 20 ml of phosphorus oxychloride with vigorous stirring. After completion, the mixture is warmed under reflux for a further 1.5 h.
For work-up, the cooled batch is stirred in portions into 100 ml of ice-water and subsequently adjusted to pH 12 using conc. NaOH solution. The aque- ous phase is extracted with ethyl acetate. The combined organic phases are dried over sodium sulfate, and the solvent is removed in vacuo. The 7- chloro-[1,2 4]triazolo[1,5-a]pyrimidine obtained is employed in the following reaction without further purification; m.p. 190° [lit. 186 — 187°C]; £ HPLC: 0.920 min; MS: [157.0]. - 25 400 mg of (R)-2-{naphthalen-1-yloxymethyl)pyrrolidine, 500 mg of the 7-chloro-[1,2,4]triazolo[1,5-a]pyrimidine prepared above and 650 mg of
N-ethyldiisopropylamine are heated at 130°C in a microwave for 3 h in 40 ml of 1-butanol. The butanol is subsequently removed in vacuo, the residue is taken up in ethyl acetate, mixed with water, adjusted to pH 12 using 1 N
NaOH solution, phases are separated, the organic phase is dried over sodium sulfate, evaporated and chromatographed on silica gel, giving 640 mg of "A1"; m.p. 74 - 75°: 3 HPLC: 2.386 min; MS: [346.1];
'H NMR (500 MHz, ds-DMSO} 8 [ppm] 8.43 (s, 1H), 8.31 (d, 1H, J = 5.7 Hz), 7.83 (d, 1H,J=8.1 Hz), 7.71 (d, 1H, J = 8.1 Hz), 7.49 (ddd, 1H, J = 1.3 Hz,
J=6.9Hz J=8.1Hz), 7.44 (d, 1H, J = 8.2 Hz), 7.40 (ddd, 1H, J = 1.3 Hz,
J=68Hz J=81Hz),735( 1H,J=79Hz),6.9(d, 1H, J=7.7 Hz), 8.43 (d, 1H, J = 5.7 Hz), 5.74 (br. m, 1H), 4.39 (dd, 1H, J =5.2 Hz, J = 9.7 Hz), 4.20 (dd, 1H, J = 6.5 Hz, J = 9.7 Hz), 4.00 (br. m, 1H), 3.80 (br. m, 1H), 2.33 — 2.22 (m, 3H), 2.10 (m, 1H).
Example 2 - The preparation of 7-pyrazol-1-yl-[1,2 4]triazolo[1,5-a]pyrimidine ("A2") is carried out analogously to the following scheme ¢
Ci N
JN N N
N ZN” NZ
TGs TUL
N N N N
300 mg of 7-chloro-[1,2,4ltriazolo[1,5-alpyrimidine and 700 mg of pyrazole ) are heated together to 120°C, forming a melt. After cooling, the batch is tL 25 partially dissolved in methanol, the insoluble residue is separated off after min. and dried in air.
HPLC: 1.384 min; MS: [187.1]; m.p. 191 - 193°; "H NMR (500 MHz, dg-DMSO}) & [ppm] 9.43 (d, 1H, 2.8 Hz), 8.95 (d, 1H, J = 30 5.0 Hz), 8.85 (s, iH), 8.16 (d, 1H, J = 1.5 Hz), 7.81 (d, 1H, J = 5.0 Hz), 6.85 (dd, 1H, J=1.86 J, = 2.8 Hz).
Example 3
The preparation of 5-[(R)-2-(naphthalen-1-yloxymethylpyrrolidin-1-yllimidazo- [1,2-a]pyrimidine ("A3"} is carried out analogously to the following scheme on () ° ft
OH cl N
OH
O07 "OH a ZN _b ry on
HN" N a) 1 9 g of malic acid and 5.6 g of 2-aminoimidazole are added to 25 ml of fuming sulfuric acid at 0°C. This solution is stirred at RT for 12 h and under reflux for one hour. For work-up, the batch is added to 100 g of ice and adjusted to pH = 6 using conc. NaOH solution. b} — ¢) analogous to Example 1
Example 4
The preparation of 5-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-y{]-[1,2,4]- triazolo[4,3-a]pyrimidine ("A4") is carried out analogously to the following ( 5 scheme
A oS A SD ( pL PS Qo Qe
A : . , o — N ZN c x ee NH, —nm N
Sal Se SN 2 Oy
H N™ SN \y a) 327 mg of 2,4-dichloropyrimidine are dissolved in 20 ml of isopropanol, and 0.8 ml of N-ethyldiisopropylamine and 500 mg of (R)-2-(naphthalen-1-yloxy- methyl}pyrrolidine are added. This mixture is warmed at 80°C for 6 h. After ° cooling, the batch is poured into 40 ml of water and 40 ml of ethyl acetate.
After phase separation, the organic phase is dried, evaporated and chromato- graphed on silica gel, giving 480 mg of 2-chloro-4-[(R)-2-(naphthalen-1-yloxy- methyl)pyrrolidin1-yl]pyrimidine as colourless oil;
HPLC: 2.831; MS [340.1]. b) 480 mg of 2-chloro-4-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin 1-yl]pyrimidine are warmed at 80°C for 6 h with 5 g of hydrazine hydrate, giving 420 mg of {4-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin1-yljpyrimidin-2-ylthydrazine;
HPLC: 1.751; MS [336.1]. c) 210 mg of {4-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin1-yljpyrimidin-2-yl}- hydrazine are warmed at 120°C for 3 h in 10 ml of triethyl! orthoformate. The o-[(R)-2-(naphthalen-1-yloxymethyl)pyrrolidin-1-yi]-[1,2,4]triazolo[4, 3-a]- oo pyrimidine crystals which deposit are filtered off with suction and dried in air: “725 HPLC: 1.846 min: MS [346.2]: 'H NMR (500 MHz, de-DMSO) d [ppm] 8.71 (s, 1H), 8.55 (d, 1H, J = 7.6 Hz), 8.14 (br. s, 1H), 7.86 (dd, 1H, J = 1.3 Hz, J= 7.6 Hz), 7.53 (dd, 1H, J = 1.3 Hz,
J=6.7Hz),7.49 (dd, 1H, J=1.5Hz, J = 8.9 Hz), 7.47 (d, 1H, J = 8.3 Hz), 7.39 (t, 1H, J =7.9 Hz), 7.08 (br. s, 1H), 4.75 (br. s, 1H), 4.46 (br. s, 1H), 4.27 (br. s,
TH), 3.76 (br. m, 1H), 3.80 (br. s, 1H), 2.27 (br. m, 1H), 2.21 (br. m, 2H), 2.08 (br. m, 1H).
Example 5
The preparation of 5-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)quinoline ("A5") is carried out analogously to the following scheme [ ). oH =
N [ \., oH [ \. oms LN cl N N {Pr
Z>~n-N b _ c
Bo ENGST
CL NTN N STON a) 1 g of commercially available (D)-prolinol, 1.5 g of 7-chloro-[1,2,4]triazolo- [1,5-a]pyrimidine and 2.6 g of N-ethyldiisopropylamine are heated at 130°C in a microwave for 3 h in 60 ml of 1-butancl. The butanol is subsequently removed in vacuo, the residue is taken up in ethyl acetate, mixed with water, adjusted to pH 12 using 1 N NaOH solution, phases are separated, the organic phase is dried over sodium sulfate, evaporated and chromato- graphed on silica gel, giving 1.7 g of ((R)-1-[1,2 4]triazolo[1,5-a]pyrimidin-7- { 25 ylpyrrolidin-2-yl)methanol as beige crystals;
HPLC: 1.086 min; MS: [220.1]. b) 1.5 g of ((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yIpyrrolidin-2-yl)methanol are dissolved in 15 ml of dichloromethane with stirring, and 1.9 ml of triethylamine are added. This solution is cooled to 0°C, and a solution of 0.8 ml of methane- sulfonyl chloride in 5 ml of dichloromethane is added dropwise. When the addition is complete, the mixture is allowed to warm to RT for 12 h. For work- up, the solution is poured into equal proportions by volume of water, the organic phase is extracted to exhaustion with ethyl acetate, the combined organic phases are dried over sodium sulfate, filtered off with suction, evapo- rated and chromatographed on silica gel, giving 1.1 g of ((R)-1-[1,2,4]triazolo- [1,5-a]pyrimidin-7-ylpyrrolidin-2-ylymethyl methanesulfonate as colourless oil; : HPLC: 1.424 min; MS [298.1]. c) 250 mg of ((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl) methyl methanesulfonate, 120 mg of 5-hydroxyquinoline and 1 g of caesium carbon- ate are suspended in 20 ml of DMF and stirred at 80°C for 12 h. The solvent is £m subsequently stripped off in vacuo, the residue is partitioned between ethyl acetate and water, the organic phase is dried and purified by chromatography on silica gel, giving 90 mg of 5-[(R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yI- pyrrolidin-2-ylmethoxyquinoline as beige crystals; HPLC: 1.312 min; MS [347.1]; m.p. 93 — 95°; 'H NMR (500 MHz, ds-DMSO) 8 [ppm] 8.67 (d, 1H, J = 5.2 Hz), 8.42 (s, 1H), 8.31 (d, 1H, J =5.6 Hz), 7.91 (d, 1H, J = 9.0 Hz), 7.71 (m, 2H), 7.47 (ddd, 1H,
J=10Hz,J=68Hz, J=78Hz),7.02 (d, 1H, J=52Hz),6.43 (d, 1H, J = 5.6 Hz), 5.76 (br. m, 1H), 4.50 (dd, 1H, J = 5.2 Hz, J = 8.9 Hz), 4.32 (dd, 1H,
J=6.3 Hz, J=9.9 Hz), 3.98 (m, 1H), 3.78 (m, 1H), 2.26 (m, 3H, 2.11 (m, 1H). £ Example 6 = 95
The preparation of 7-[2-(naphthalen-1-yloxymethyhimidazol-1-yljtriazolo[1,5-a]- pyrimidine ("AB") is carried out analogously to the following scheme
N N b N N » o 2} o 2 UN one UN od
N N N N
H H H
( ; 0 { ? { ?
No] N
ZN { d...0 0 N f os e N
Ceo. 0 20
H Js S $C) - SON a) 5 g of imidazole-2-carboxaldehyde are heated under reflux for 12 h with 7 g of 2,3-dihydrofuran and 0.8 g of ptoluenesulfonic acid in 100 ml of THF.
After cooling, the solvent is removed in vacuo, and the residue is partitioned between ethyl acetate and water. The organic phase is dried, filtered off, evaporated and purified on silica gel, giving 4.4 g of a yellow oil, which is detected as hydrate in the HPLC;
HPLC: 0.476; MS: [185.1]. - 25 4.4 g of [1-(tetrahydrofuran-2-yl)-1H-imidazol-2-yl]carboxaldehyde are dis- solved in 100 ml of methanol under nitrogen, and 1.9 g of sodium boro- hydride are added in portions. After 12 h, the reaction is complete, and the solvent is removed in vacuo. The residue is partitioned between water and ethyl acetate, the organic phase is dried, filtered off with suction and evapo- rated. The product is reacted further directly. c) 2.8 g of [1-(tetrahydrofuran-2-yl}-1H-imidazol-2-yl]methanol are dissolved in 100 mi of dichloromethane under nitrogen, and 2.4 ml of thionyl! chloride are added dropwise at 0°C. When the addition is complete, the mixture is allowed to warm to RT for 12h. The precipitate of 2-chloromethyl)-1-(tetra- hydrofuran-2-yl)-1H-imidazole hydrochloride which deposits is filtered off with suction, dried in air (1.6 g) and employed in the following reaction with- ° out further purification;
HPLC: 0.559; MS: [187.1]. d) 800 mg of 2-chloromethyl)-1-(tetrahydrofuran-2-yl)-1H-imidazole hydro- po chloride and 390 mg of 1-naphthol are stirred at 80°C for 12 h with 1.2 g of oo potassium carbonate in 50 ml of DMF. The batch is partitioned between equal porportions of ethyl acetate and water, the organic phase is dried, fil- tered off, evaporated to dryness, and the resultant 500 mg of brown oil are reacted further directly; HPLC: 1.672; MS: [295.1]. e) 500 mg of 2-(naphthylen-1-yloxymethyl)-1-(tetrahydrofuran-2-yl)- 1H-imida- zole are warmed at 80°C for 1h with 1.3 ml of triflucroacetic acid in 10 mi of 1,2-dichloroethane. The volatile constituents are removed in vacuo, giving 380 mg of 2-(naphthalen-1-yloxymethyl)-1H-imidazole, which is employed in
Fo the following reaction without further purification. el 25 f) Analogous to the final step of Example 1, giving "AB".
The following compounds are obtained analogously to Examples 1-6
Compound Structure and/or name M.p. [°C}| HPLC-MS;
No. rt: [M+H']® "A8" 156-157| 1.475 min . oO [347.1]
N ~~ = 0 a. oN
LA
4-((R)-1-{1,2 4]Triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-yimethoxy)quinoline ” H NMR (500 MHz, ds-DMSO) & [ppm] 8.86 (dd, 1H, J = 1.7 Hz, J = 4.2 Hz), po 8.42 (s, 1H), 8.31 (d, 1H, J = 5.6 Hz), 8.09 (d, 1H, J = 8.2 Hz), 7.58 (m, 2H), 7.42 (dd, 1H, J=4.2 Hz, J = 8.4 Hz), 7.05 (d, 1H, J =7.58 Hz), 6.42 (d, 1H, J =5.7 Hz), 5.72 (br. m, 1H), 4.43 (dd, 1H, J = 5.1 Hz, J = 9.8 Hz), 4.24 (dd, 1H, J =6.5 Hz, J = 9.8 Hz), 3.99 (br. m, 1H), 3.79 (br. m, 1H), 2.25 (m, 3H), 2.10 (m, 1H). "AQ" OS F 77-78 | 1.804 min
N N—/ oF [431.1] 7 — F { N= 0 ~C
N= 4 \ N 4-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- { 7 - pyrrolidin-2-ylmethoxy)}-6-trifluoromethoxy- quinoline
H NMR (500 MHz, dg-DMSQ) & [ppm] 8.75 (d, 1H, J = 5.1 Hz), 8.38 (s, 1H), 8.30 (d, 1H, J=5.6 Hz), 8.06 (d, 1H, J = 9.1 Hz), 7.71 (dd, 1H, J=2.2 Hz, J =0.2Hz), 7.66 (s, 1H), 7.15 (d, 1H, J = 5.2 Hz), 6.44 (d, 1H, 5.6 Hz), 5.72 (br. m, 1H), 4.55 (dd, 1H, J = 5.2 Hz, J = 10.0 Hz), 4.37 (dd, 1H, J = 6.3 Hz,
J =10.0 Hz), 3.89 (br. m, 1H), 3.80 (br. m, 1H), 2.24 (m, 3H), 2.11 (m, 1H).
"A10" FF 171- | 1.806 min
N (7 " 172 1 1415.1] -) ° ~
N=( D " \ 4-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-6-trifluoromethyl- quinoline
H NMR (500 MHz, dg-DMSO) 8 [ppm] 8.85 (d, 1H, J = 5.2 Hz), 8.35 (s, 1H), = 8.29 (d, 1H, J = 5.7 Hz), 8.18 (s, 1H), 8.12 (d, 1H, J = 8.8 Hz), 7.97 (dd, 1H, " J=2.0Hz, J =8.8Hz), 7.23 (d, 1H, J = 5.3 Hz), 6.46 (d, 1H, J = 5.7 Hz), 5.72 (br. m, 1H), 4.58 (dd, 1H, J = 5.5 Hz, J = 10.1 Hz), 4.41 (dd, 1H, J =6.6 Hz, J = 10.1 Hz), 4.01 (br. m, 1H), 3.82 (br. m, 1H), 2.25 (m, 3H), 2.11 (m, 1H). "A11" oN 2.472 min
Lo | = [498.2] oy 7 “ 07 NH
OL
N-4-Fluorobenzyl-4-((R)-1-[1,2,4]triazolo- { ; 25 [1,5-alpyrimidin-7-ylpyrrolidin-2-ylmethoxy)- quinoline-2-carboxamide
H NMR (500 MHz, ds-DMSO) & [ppm] 9.39 (t, 1H, J = 6.4 Hz), 8.48 (s, 1H), 8.31 (d, 1H, J = 5.6 Hz), 8.03 (d, 1H, J = 8.40 Hz), 7.81 (ddd, J = 1.2 Hz, J = 7.0Hz, J=8.3Hz),7.75(d, 1H, J=8.5 Hz), 7.73 (s, 1H), 7.57 (ddd, 1H, J = 0.8Hz, J=72Hz, J=7.9Hz), 7.39 (dd, 2H, J =5.6 Hz, J = 8.5 Hz), 7.14 (1, 2H, J =8.9 Hz), 6.42 (d, 1H, J = 5.8 Hz), 5.79 (br. m, 1H), 4.64 (dd, 1H, J = 9.5 Hz, J=10.0 Hz), 4.52 (d, 2H, J =6.4 Hz), 4.43 (dd, 1H, J=6.7 Hz, J = 10.0 Hz), 3.87 (br. m, 1H), 3.76 (br. m, 1H), 2.25 (m, 3H), 2.11 (m, 1H).
"A12" 2.537 min [5613.2] oN 7H ha 0
No J ~~
N N
Cd
F
N-[2-(4-Fluorophenyl)ethyl]-4-((R)-1-[1,2,4]- triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-y!- ey methoxy)quinoline-2-carboxamide - H NMR (500 MHz, ds-DMSO) & [ppm] 8.87 (t, 1H, J = 6.1 Hz), 8.47 (s, 1H), 8.31, 1H, J = 54 Hz), 8.00 (d, 1H, J = 8.3 Hz), 7.81 (ddd, 1H, J =1.4 Hz, J =6.9Hz,J=83Hz),7.75(d, 1H, J=8.2 Hz), 7.71 (s, 1H), 7.56 (ddd, 1H, J =1.1Hz, J=6.9 Hz, J=8.2 Hz), 7.29 (dd, 2H, J= 5.6 Hz, J = 8.5 Hz), 7.10 (1, 2H, J = 8.9 Hz), 6.42 (d, 1H, J = 5.7 Hz), 5.78 (br. m, 1H), 4.64 (dd, 1H; J = 9.5 Hz, J =10.2 Hz), 4.43 (dd, 1H, J =6.7 Hz, J = 10.2 Hz), 3.97 (br. m, 1H), 3.76 (br. m, 1H}, 3.57 (q, 2H, J = 6.5 Hz), 2.89 (t, 2H, J = 7.5 Hz), 2.26 (m, 3H), 2.11 (m, 1H). "A13" 2.013 min
LA. o [418.1] oo ox
Pa
N7 N 0 "
N-Ethyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin- 7-ylpyrrolidin-2-yimethoxy)quinoline-2- carboxamide
H NMR (500 MHz, dg-DMSO) & [ppm] 8.83 (t, 1H, J = 6.0 Hz), 8.48 (s, 1H), 8.31 (d, 1H, J = 5.7 Hz), 8.02 (d, 1H, J = 8.4 Hz), 7.80 (ddd, 1H, J = 1.3 Hz, J = 6.9 Hz, 8.3 Hz), 7.75 (d, 1H, J = 8.2 Hz), 7.72 (s, 1H), 7.56 (ddd, 1H, J = 0.9 Hz, J=7.1Hz J=8.0Hz), 6.42 (d, 1H, J = 5.7 Hz), 5.78 (br. m, 1H), 4.64 (dd, 1H, J = 5.4 Hz, J = 10.0 Hz), 4.43 (dd, 1H, J = 6.7 Hz, J = 10.0 Hz), 3.97 (br. m, 1H), 3.77 (br. m, 1H), 3.37 (g, 2H, J = 7.2 Hz), 2.26 (m, 3H), 2.11 (m, 1H), 1.16 (t, 3H, J =7.2 Hz). "A14" N 195- | 1.917 min (la 197 | 1303.1]
Az
N N
7-[2-(Naphthalen-1-yloxymethyl)imidazol-1-yl]- [1,2,4]triazolo[1,5-a]pyrimidine
H NMR (500 MHz, dg-DMSQ) & [ppm] 8.90 (d, 1H, J =4.7 Hz), 8.71 (s, 1H), 7.84 (d, 1H, J=15Hz), 7.76 (d, 1H, J =8.2 Hz), 7.72 (d, 1H, J = 4.7 Hz), 7.41 (m, 2H), 7.33 (t, 1H, J = 7.9 Hz), 7.31 (d, 1H, J = 1.5 Hz), 7.15 (ddd, 1H,
J=10Hz,J=6.9Hz, J=83Hz),7.00(d, 1H, J=7.5Hz), 6.89 (d, 1H, J = 8.3 Hz), 5.54 (s, 2H). "A15" 115- | 1.776 min eo oad M71 1345.1] . oF ®
Le 5-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1- yllimidazo[1,2-a]pyrimidine
H NMR (500 MHz, de-DMSO) & [ppm] 8.19 (d, 1H, J = 5.2 Hz), 7.95 (d, 1H,
J=16Hz),7.80(d, 1H, J=8.2 Hz), 7.61 (d, 1H, J = 8.2 Hz), 7.57 (d, 1H, J =1.6 Hz), 7.47 (ddd, 1H,J= 1.3 Hz, J=68Hz, J=8.1 Hz), 7.41 (d, 1H, J = 8.2 Hz), 7.36 (ddd, 1H, J=1.3 Hz, J=6.9 Hz, J=83Hz), 7.31 (t, 1H, J = 7.8 Hz), 6.87 (d, 1H, J =7.7 Hz), 6.48 (d, 1H, J = 5.2 Hz), 4.86 (m, 1H), 4.22 (dd, 1H, J = 5.4 Hz, J = 10.1 Hz), 4.15 (dd, 1H, J = 4.7 Hz, J = 10.1 Hz), 3.99 (ddd, 1H, J=86.4 Hz, J=9.3 Hz, J= 15.8 Hz), 3.72 (ddd, 1H, J=2.3 Hz, J = 7.9 Hz, J = 9.6 Hz), 2.44 (m, 1H), 2.12 (m, 2H), 1.95 (m, 1H). "A16" 72-74] 2.195 min 0 Lo 5 [347.1] ys I
SE
1-((R)-1-[1,2,4]Triazolo[1,5-alpyrimidin-7-yl- pyrrolidin-2-ylmethoxy)isoquinoline
H NMR (500 MHz, dg-DMSO) & [ppm] 8.33 (s, 1H), 8.27 (d, 1H, J = 5.7 Hz), 7.87 (d, 1H, J =5.8 Hz), 7.85 (d, 1H, J = 8.5 Hz), 7.72 (m, 2H), 7.52 (ddd, 1H, J=1.0Hz, J=7.1 Hz, J =8.2 Hz), 7.34 (d, 1H, J = 5.7 Hz), 6.43 (d, TH, 9.7 Hz), 5.64 (br. s, 1H), 4.64 (d, 2H, J = 5.5 Hz), 3.98 (br. s, 1H), 3.80 (br. m, 1H), 2.29 —- 2.18 (m, 3H), 2.08 (m, 1H) pe "A1T7" Za 158- | 1.408 min
LJ 0 | 159 | 347.1] oo 4
A =
N N
5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)isoquinoline
H NMR (500 MHz, dg-DMSQ) & [ppm] 9.24 (s, 1H), 8.41 {(s. 1H), 8.31 (d, 1H,
J=57Hz),764 (d, 1H, J=82Hz), 7.54 (d, 1H; J=82 Hz), 7.53 (d, 1H, J )3=111Hz),7.23(d, 1H, J=7.6 Hz), 6.43 (d, 1H, J = 5.7 Hz), 5.72 (br. 5, 1H), 4.44 (dd, 1H, J=5.1 Hz, J=9.8 Hz), 4.23 (dd, 1H, J=6.4 Hz, J= 9.8
Hz), 4.00 (br. s, 1H), 3.79 (br. m, 1H), 2.29 (m, 3H), 2.11 (m, 1H) "A18" oO 1.845 min
AN TY [515.2] = : 5 oO ed
C Cp NA ! N
N=/
N-[3-(2-Oxopyrrolidin-1-yl)propyl}-4-((R)-1- [1,2,4]triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2- ylmethoxy)quinoline-2-carboxamide "A19" Oo 1.666 min ww ~~ [372.2] 0 .
TY
Cryo
Le
Ethyl 5-methyl-4-((R)-1-[1,2,4]triazolo[1,5-a}- {5 05 pyrimidin-7-ylpyrrolidin-2-ylmethoxy)-1H- pyrazole-3-carboxylate
. -B2- "A20" 1.498 min
L Jo Le [488.3]
MY
NP ™
NT
Lo (2-Morpholin-4-ylethyl)-[4-((R)-1-[1,2,4]- triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- oo methoxy)naphthalen-1-ylmethyljamine
L "ADA! 1.423 min 9 [502.3] ~) yd N
N 2 oO 2
Ly 0 (3-Morpholin-4-ylpropyl)-[4-((R)-1-[1,2.4]- triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)naphthalen-1-ylmethyllamine "A22" o 2.379 min {J Ns N [480.2] _ 0 ~~
LO
Crd 1 N
N=/
N-Benzyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin 7-ylpyrrolidin-2-ylmethoxy)quinoline-2- carboxamide
H NMR (500 MHz, dg-DMSO) 6 [ppm] 8.85 (d, J = 1.7, 1H), 8.79 (dd, J = 4.8, 1.6, 1H), 8.35 (s, 1H), 8.31 (d, J = 5.6, 1H), 8.02 (dt, J = 7.9, 1.8, 1H), 7.50 (dd, J=7.9,4.9, 1H), 6.42 (d, J = 5.7, 1H), 5.58 (br. m, 1H), 4.53 (dd, J = 11.3, 5.7, 1H), 4.46 (dd, J = 11.3, 5.5, 1H), 3.96 (br. m, 1H), 3.76 (br. m, 1H), 2.30 — 1.97 (m, 4H) "AT71" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- 1.917 min pyrrolidin-2-yimethyl benzoate "AT2" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- 2.111 min 7 pyrrolidin-2-yimethyl 3-ethoxybenzoate £m H NMR (500 MHz, dg-DMSO) & [ppm] 8.36 (s, 1H), 8.31 (d, J = 5.6, 1H), - 7.35(t,d=7.9 1H), 7.25(d,J=7.7, 1H), 7.24 - 7.14 (m, 2H), 6.42 (d, J = 5.7, 1H), 5.56 (br. m, 1H), 4.49 (dd, J = 11.3, 5.7, 1H), 4.41 (dd, J = 11.3, 2.5, 1H), 4.02 (q, J = 7.0, 3H), 3.95 (br. m, 1H), 3.83 — 3.71 (m, 1H), 2.29 — 2.13 (m, 2H), 2.07 (m, 2H), 1.34 (t, J = 7.0, 4H) "A73" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yi- 2.086 min pyrrolidin-2-ylmethyl 5-chicro-2-fluorcbenzoate | oma
H NMR (500 MHz, ds-DMSO) & [pprn] 8.34 (s, 1H), 8.31 (d, J = 5.6, 1H), 7.78 =7.70 (m, 1H), 7.61 (dd, J = 6.1, 2.7, 1H), 7.43 —- 7.30 (m, 1H), 6.41 (d,
J=5.7, 1H), 5.54 (br. m, 1H}, 4.52 (dd, J = 11.3, 5.7, 1H), 4.42 (dd, J = 11.3, 2.5, TH), 3.95 (br. m, 1H), 3.84 — 3.65 (m, 1H), 2.26 — 2.13 (m, 2H), 2.13 —
S oe 1.97 (m, 2H) "AT74" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- 2.059 min ramen || 20 "A75" oS 0 1.570 min “ Mn N g aN [452.2]
N=( h ~ > NH,
NE
3-Aminopropyl! 8-((R)-1-[1,2,4]triazolo[1,5-a]- pyrimidin-7-ylpyrrolidin-2-yImethoxy)-3,4- dihydro-1H-isoquinoline-2-carboxylate i -79- "A786" oS 1.181 min
I » “eq No Nm, Hoel
LD =D
NT
3-[8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H- isoquinolin-2-yllpropylamine "ATT" | 7-[(R)-2-(Naphthalen-1-yloxymethylpyrrolidin-1- 2.450 min ator sassee || rn { H NMR (500 MHz, de-DMSO) & [ppm] 8.51 (s, 1H), 8.38 (s, 1H), 7.70 (d, J = 7.9, 1H), 7.46 — 7.31 (m, 4H), 7.26 (m, 1H), 6.85 (m, 1H), 5.80 (br. m, 1H), 5.00 (br. m, 1H), 4.50 (m, 1H) 4.41 (dd, J = 9.6, 3.4, 1H), 4.35 (br. m 1H), 2.25 (m, 3H), 2.07 (m, 1H) "A78" 0 1.697 min
J [349.2] ¢ oN
N={ 3 0
N
2-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethyl)isoindole-1,3-dione (os "A79" (R)-1-[1,2,4]Triazolo[1.5-a]pyrimidin-7-yI- 1.829 min or pyrrolidin-2-ylmethyl 3-cyanobenzoate | en "A80" 235 - | 2.055 min
Lo ® 236 | 1361.1] wT
N™ nN 7-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1- yl]-{1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine
"A81" 0 2.023 min
ON yy [377.2] =" N
Methyl 2-(1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethyl)-1H-indole-5-carboxylate
H NMR (500 MHz, ds-DMSO) & [ppm] 11.42 (s, 1H), 8.44 (s, 1H), 8.30 (d, J =5.7, 1H), 8.14 (d, J = 15.1, 1H), 7.68 (dd, J = 8.5, 1.5, 1H), 7.41 (d, J = 8.5, 1H), 6.49 ~ 6.33 (m, 2H), 5.24 (br. m, 1H), 4.01 (br. m, 1H), 3.83 (s, 3H), _ 3.23 (dd, J=14.4, 3.2, 1H), 3.06 (dd, J = 14.4, 7.2, 2H), 2.93 (dd, J = 14.4, “ 9.7, 1H), 2.07 — 1.81 (m, 4H), 1.25 - 1.11 (m, 2H) "A82" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl- 2.251 min o pyrrolidin-2-ylmethyl 3-trifluoromethoxy- BE benzoate
H NMR (600 MHz, ds-DMSO) & [ppm] 8.33 (s, 1H), 8.29 (d, J = 5.6, 1H), 7.68 (br.d, J=7.6, 1H), 7.65 (br. d, J=8.2, 1H), 7.61 (d, J= 7.8, 1H), 7.58 (m, 1H), 6.41 (d, J = 5.7, 1H), 5.58 (s, 1H), 4.51 (dd, J = 11.3, 5.7, 1H), 4.44 (dd, d= 11.3, 5.7, 1H), 3.95 (br. m, 1H), 3.75 (br. m, 1H), 2.27 — 2.00 (m, 4H) "AB3" 168- | 1.094 min
Lon 170 | 1220.1]
Ls 0 - PW
N N
((R)-1-[1,2,4]Triazolo[1,5-alpyrimidin-7-yl- pyrrolidin-2-ylYmethanol
H NMR (500 MHz, dg-DMSO) & [ppm] 8.37 (s, 1H), 8.27 (t, J = 6.6, 1H), 6.30 (d, J = 5.7, 1H), 4.94 (s, 1H), 4.87 (t, J = 5.7, 1H), 3.96 (s, 1H), 3.79 (d,
J =6.3, 1H), 3.57 (ddd, J = 10.8, 5.4, 3.9, 1H), 3.45 (dt, J = 11.0, 6.3, 1H), 2.15 -2.01 (m, 3H), 2.00 — 1.91 (m, 1H)
"AB4" H 1.721 min (Ps [377.1] ory ©
A =
N° °N 4-Fluoro-N-({R)-1-[1,2,4]triazolo[1,5-a]- pyrimidin-7-ylpyrrolidin-2-ylmethylbenzene- sulfonamide
H NMR (500 MHz, de-DMSO) & [ppm] 8.32 (s, 1H), 8.25 (d, J = 5.7, 1H), 797 J=64 1H),7.88-7.73 (m, 2H), 7.47 — 7.30 (m, 2H), 6.22 (d, J = { 5.8, 1H), 4.88 (br. m, 1H), 3.94 (br. m, 1H), 3.76 (br. m, 1H), 3.06 (ddd, J = ) 13.3, 5.9, 3.7, 1H), 3.01 — 2.88 (m, 1H), 2.14 — 1.89 (m, 4H) "A85" Ho = 1.718 min
J Or [279.2] = I 2-Methyl-2-[4-([1,2,4]triazolo[1,5-alpyrimidin-7- ylamino)phenyl]propionitrile
H NMR (500 MHz, de-DMSO) d [ppm] 8.82 (s, 1H), 8.45 (d, J = 6.0, 1H), 7.67 (d, J=8.7, 2H), 7.54 (d, J = 8.7, 2H), 6.63 (d, J = 6.0, 3H), 1.74 (s, 6H) "ABB" 1.939 min {> . op) [356.2]
N a
Try
PN
30 7-[2-(2-Ethoxyphenoxymethyl)morpholin-4-yl]- [1,2 4}triazolo[1,5-a]pyrimidine
H NMR (500 MHz, dg-DMSO) 8 [ppm] 8.52 (s, 1H), 7.03 (dd, J = 7.5, 2.0, 1H), 6.98 (dd, J =7.7, 1.9, 1H), 6.95 — 6.84 (m, 1H), 6.68 (d, J = 5.5, 1H), 468(d, J=12.7, 1H), 4.53 (d, J = 12.7 1H), 4.16 — 4.09 (m, 1H), 4.08 — 4.00 (m, 4H), 3.80 (td, J = 11.6, 2.5, 1H), 3.30 — 3.16 (m, 1H), 1.32 (t, J = 7.0, 2H)
i -82 - "A87" Yo 1.337min
SN [314.2]
N.__N, hy OH
N OH
4-(4-[1,2,4]Triazolo[1,5-alpyrimidin-7-yl- morpholin-2-yl)\benzene-1,2-dioi
H NMR (500 MHz, de-DMSO) d [ppm] 8.86 (br. s, 2H), 8.52 (s, 1H), 8.48 (d,
J=258.5 1H), 6.83 (d, J = 1.8, 1H), 6.79 —- 6.63 (m, 3H), 4.66 (d, J = 12.8, 1H), 4.55 (dd, J = 10.5, 2.3, 1H), 4.50 (br. d, J = 12.9, 1H),4.11 (dd, J = 11.8, 2.0, £ 1H), 3.86 (id, J = 11.7, 2.4, 1H), 3.12 (dd, J = 12.7, 10.6, 1H)
N N [218.2] oN
NN
7-(2-Oxa-5-azabicyclo[2.2. 1]hept-5-yI)-[1,2,4]- triazolo[1,5-a]pyrimidine
H NMR (500 MHz, de-DMSO) 0 [ppra] 8.40 (s, 1H), 8.29 (d, J = 5.6, 1H), 6.33 (s, 1H), 4.76 (s, 1H), 3.86 (dt, J = 7.8, 4.6, 3H), 3.34 (br. m, 5H), 2.07 (dd, J=10.2, 2.1, 1H), 1.98 (d, J = 10.2, 1H)
A89 AYE 1.138 min { \__/ [206.2] - 2s oN
NN
7-Morpholin-4-yl-[1,2 4]triazolo[1,5-a]pyrimidine
H NMR (500 MHz, dg-DMSO) & [ppm] 8.52 (s, 1H), 8.50 (d, J = 5.5, 1H), 6.65 (d, J = 5.5, 1H), 3.88 (dd, J = 5.8, 3.5, 5H), 3.81 (dd, J = 5.7, 3.4, 5H), 3.34 (br. m, 5H)
"A90" 1.426 min / ( [234.2]
Nn 0
N=
NN
7-(2,6-Dimethylmorpholin-4-yl)-[1,2 4]triazolo- [1,5-a]pyrimidine
H NMR (500 MHz, ds-DMSO) & [ppm] 8.51 (s, 1H), 8.48 (d, J = 5.5, 1H), 6.70 (d, J=5.5, 1H), 4.55 (d, J = 12.6, 2H), 3.79 (m, 2H), 2.81 (dd, J = 12.6,
BN 10.6, 2H), 1.17 (d, J = 86.2, 6H)
LC "AGT" —_N_ 0.923 min
NNR [205.2]
HN A
4-Morpholin-4-yl-7H-pyrrolo[2, 3-d]pyrimidine
H NMR (500 MHz, ds-DMSQO) & [ppm] 12.10 (br. s, 1H), 8.25 (s, 1H), 7.30 (dd, J =3.3, 2.4, 1H), 6.82 — 6.68 (m. 1H), 3.97 — 3.82 (m, 4H), 3.82 —~ 3.67 (m, 4H) "A92" O 1.622 min —
No. N [321.2]
Cedi i] .. N=( N . N= - 25
N-[4-(Cyanodimethylmethyl)phenyi]-N-[1,2,4]- triazolo[1,5-a]pyrimidin-7-ylacetamide
"A93" H 1.587 min i) [5688.3] (7°
N N— O
C= N -° " pa
A
H N—7 tert-Butyl ((R)-1-(1H-imidazol-4-yimethyl)-2-oxo- 2-{8-[(R}-1-(9H-purin-8-yl)pyrrolidin-2-yl- methoxy]-3,4-dihydro-1H-isoquinolin-2-yl}ethyl)- . carbamate
Table 1 inhibition of MetAP-2
ICso of compounds of the formula | according to the invention
Compound No.| ICs enzyme Compound [ No.
A
CO oo [ae
OF he] mer [A] 2 0 2s
I a CC EE mE [A | me
I I EE
; ee * er | A | wr | s mC [A | wo | 8
Co] ower | oA owe A 1 n 84"
I CC EE
ICs: 10 nM - 1 uM = A 1TuM-10uM =B > 10 uM =C £0 The following examples relate to medicaments:
Example A: Injection vials
A solution of 100 g of an active ingredient of the formula | and 5 g of disodium hydrogenphosphate in 3 [| of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.
Example B: Suppositories
A mixture of 20 g of an active ingredient of the formula | with 100 g of soya { 05 lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.
Example C: Solution
A solution is prepared from 1 g of an active ingredient of the formula |, 9.38 g of NaH,PO, - 2 H,0, 28.48 g of Na;HPO, - 12 H,0 and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solu- tion is made up to 1 | and sterilised by irradiation. This solution can be used in the form of eye drops.
Example D: Ointment 500 mg of an active ingredient of the formula | are mixed with 99.5 g of Vase- line under aseptic conditions.
Example E: Tablets
A mixture of 1 kg of active ingredient of the formula |, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of taic and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient. € o Example F: Dragees
Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
Example G: Capsules 2 kg of active ingredient of the formula | are introduced into hard gelatine cap- sules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.
Example H: Ampoules
A solution of 1 kg of active ingredient of the formula | in 60 | of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.
Claims (1)
- Patent Claims1. Compounds of the formula R {pe Z in which denotes pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidiny!, 2-oxa-5-azabicyclo-[2.2.1]hept-5-yl, morpholinyl or N, Zz denotes imidazopyrimidinyl, imidazotriazinyl, triazolopyrimi- dinyl, triazolotriazinyl, triazolopyridazinyl, tetrazolo- pyrimidinyl, tetrazolotriazinyl, tetrazolopyridazinyl, pyrazolo- pyridazinyl or pyrrolopyrimidinyl, each of which is unsubsti- tuted or monosubstituted by R? where Z is bonded to a nitrogen of the radical D, R’ denotes H, Hal, =O, OH, NH,, A or COA, {> 05 R? denotes H, A, Hal, NH,, SCHs, OH or =O, R® denotes H or alkyl having 1-6 C atoms, X denotes O(CHy), NH, NA, OC(=0), NHSO; or is absent, Y denotes CH=CH, (CH), or is absent, R denotes H, Ar, Het or Carb’, Ar denotes phenyl, naphthyl! or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OR®, N(R%),, NO, [C(R%)2],CN, (CH2)mCOOR?, CON(R®),, NR®COA, NR®S0,A, COR®, SO,N(R®),, S(0)4A, SO20H, CH=CH-CONH(CH_),OH, NHCONH-Het,i - 89 - NHCONHA, (CH)mAr', O(CH2)mAr!, O(CHo)mHet?, O(CH2)mCOOR?, NHCONH-(CH,) ) d OHet - (CH2)mHet, CHoNH[(CH2)2014[(CH2)20]4(CH2)oNHa, CH2N(COA)CH,CH(OH)CH,OH, CHoNH(CH2)qHet, CHaN(COA)(CHy)Het, CHaN(CHO)(CHy) Het, COHet, . NHCOCH[(CH2)mCOOAINHCOO(CHa)mAr, “J NHCOCH[(CH2)mCONH,]NHCOOA, NHCOCH[(CH2)COOHINHCOOH,NHCOCH][(CH2)mHet)INHCOOA, NHCOCH[(CHa)mHet INH, NHCOCH[(CH2)mCONHz]NH,, CH=CH-COOR® and/or CH=CH-CON(R®),,Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2)mN(R®)2, NO,, (CH2)mCN,oo (CH2)mCOOR?®, CONH(CH2)mCOOH, CONH(CHz)mHet?,“og CO(CH2)mN(R®)3, CO(CHy)mNH(CH,),COOA, COO(CH2)mAT, (CH) CONH(CH,)mAT", COCH[(CH_)»CONH,]NHs, COCHI[{CH2)CONH,JNHCOOA,COCH[(CHa)mHet’]NHCOOA, COCH[(CHa)mHet’]NH,, COCH[(CH2),NHCOOAJNHCOO(CHy)mAr, COCH[(CH2)mNHa]NHCOO(CH,)mAr, COCH(NHCOA)CH,CONH,, (CH2)NHCOOA, COCH[(CH2)mCNJNHCOOA, COO(CH2)mCN,COO(CH2)mN(R®)2, CO(CH)mCON(RY,,i -90 - NRPCOA, NR®SO,A, COR®, SO,NR®, S(0),A, NHCONH- (CH2)m-Cyc-OR®, CONH(CH2),OR®, O(CH2),0R®, CHO, (CHz)mHet?, COHet?, (CH,)NH(CHa)mHet?, ; (CH2)mNH(CH2)mAr!, NH(CH2)oN(R®)2, (CH2)mAr, O(CHy)mAr" and/or =O (carbonyl oxygen), and in which one N may also be oxidised, Cyc denotes cycloalkylene having 3-7 C atoms, Ar’ denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OR®, COOR®, — CON(R®),, NR®COA, SO,NH; and/or CONH(CH2),Het?, wr Carb’ denotes R7 ’ A) 0, AS ; o © 0 0 0 oo 0 So 25 R® denotes OR®, COOR?, CON(R®), or Het’, R’ denotes (CHz),CON(R®);, (CH2),CON[(CH,CHZ)OH], or (CH2){CONH(CH,CH,)OH, Het' denotes imidazolyl, pyrazolyl or 4-chloro-2-methylpyrazolyl, Het? denotes a monocyclic aromatic or saturated heterocycle having 1 to 2 N, and/or O and/or S atoms which is unsub- stituted or mono-, di- or trisubstituted by Hal, A, OR® NHCOA, N(R®%); and/or =O (carbonyl oxygen), 3° A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, Cl, Br and/or OH, or cyclic alkyl having 3-7 C atoms, Hal denotes F, Cl, Br or |, ° m denotes 0, 1, 2, 3, 4, 5 or 6, n denotes 1 or 2, p denotes 1, 2, 3 or 4, q denotes 0, 1, 2, 3 or 4, r denotes 0, 1 or 2, pe and pharmaceutically usable salts, tautomers and stereoisomers thereof, ~ including mixtures thereof in all ratios.2. Compounds according to Claim 1 in which (2) denotes pyrrolidinyl, imidazolinyl, pyrazolyl, 2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, morpholinyl or N, and pharmaceutically usable salfs, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.p 3. Compounds according to Claim 1 or 2 in which to 25 Z denotes imidazopyrimidinyl, triazolopyrimidinyl oge de pyrrolopyrimidinyl, where Z is bonded to a nitrogen of the radical D, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.4. Compounds according to one or more of Claims 1-3 in which R denotes H, Ar or Het, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.2. Compounds according to one or more of Claims 1-4 in which Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OR®, N(R%)2, [C(R®),],CN, (CH,)mCOOR® and/or ° CHoNH(CH2)4Het, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.6. Compounds according to one or more of Claims 1-5 in which ee Het denotes a mono- or bicyclic saturated, unsaturated or aro- Lo matic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2)mN(R®)2, (CH2)mCN, (CH2)mCOOR?, CONH(CH2)mCOOH, CONH(CHz)mHet?, CO(CH,)mN(R),, CO(CH2)mNH(CH2),COOA, (CH), CONH(CH2)mAr, COCHI[(CH2)}mCONH,]NH,, COCH[(CH2)nCONH,]NHCOOA, COCH[(CHa)mHet’INHCOOA, COCH(NHCOA)CH,CONH,, (CH2)xNHCOOA, COCHI[(CH2)mCN]NHCOOA, COO(CH2)mCN, COO(CH2)mN(R%)2, CO(CH,)mCON(R®),, COR®, COHet?, O(CHa)mAr' and/or =O {carbonyl oxygen), and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.7. Compounds according to one or more of Claims 1-6 in which Ar’ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or SO,NH,, and pharmaceutically usable salts, tautomers and stereoisomers thereof, 2 including mixtures thereof in all ratios.8. Compounds according to one or more of Claims 1-7, in which i -93- Het denote pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, indolyl, dihydroindolyl, benzo- furanyl, dihydrobenzofuranyl, piperazinyl, morpholinyl, quinolinyl, isoquinolinyl, iscindolyl, dihydroguinolinyl, dihydroisoquinolinyl, tetrahydroquinolinyl, tetrahydroiso- quinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, purinyl, naphthyridinyl, pyrimidinyl, indazolyl, furyl, thienyl, imida- zolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetra- zolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]pyridinyl, £, 1,3-benzodioxolyl or benzoxazolyl, each of which is unsub- - stituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2mN(R®)2, (CH2)mCN, (CHz)mCOOR®, CONH(CH3)nCOOH, CONH(CHy)mHet?, CO{CH2)mN(R®)., CO(CH2)mNH(CH2),COOA, (CH2);CONH(CHa)mAr, COCH[(CH2) CONH,]NH, COCH[{CH2)mCONH,]NHCOOA, COCH[(CHa)mHet’INHCOOA, COCH(NHCOA)CH,CONHj, (CH2)\NHCOOA, COCH[(CH2)mCNINHCOOA, COO(CH2)mCN, COO(CHgz)mN(R®)2, CO(CH2)mCON(R®),, COR®, COHet?, - O(CHa)mAr' and/or =0, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.9. Compounds according to one or more of Claims 1-8 in which Het denotes quinolinyl, isoquinolinyl, pyrazoly! or isoindolyl, each of which is mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH)mN(R%)2, (CH2)mCN, (CH2)mCOOR®, CONH(CH2)mCOOH, CONH(CH,)mHet?, CO(CH2)mN(R®),, CO(CH2)mNH(CH,),COO0A, (CH2),CONH(CH,)mAr, COCH[{CH2)mCONH;]NH;, COCH[(CH2)mCONH,JNHCOOA,COCH[(CH2)mHet’ INHCOOA, COCH(NHCOA)CH2CONHz, (CH2)nNHCOOA, COCH[(CH32)»,CNINHCOOA, COO(CH2)nCN, COO(CH2)mN(R®)2, CO(CH2)mCON(R®),, COR®, COHet?, O(CHa)mAr’ and/or =O, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.10. Compounds according to one or more of Claims 1-9 in which - A denotes unbranched or branched alkyl having 1-6 C atoms, ) in which 1-5 H atoms may be replaced by F and/or Cl, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.11. Compounds according to one or more of Claims 1-10 in which R' denotes H, A or COA, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.12. Compounds according to one or more of Claims 1-11 in which oo R? denotes H or NHa, ol 25 and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.13. Compounds according to one or more of Claims 1-12 in which 20 Y denotes (CHa), or is absent, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.14. Compounds according to one or more of Claims 1-13 in which 3 Het? denotes imidazolyl, indolyl, isoxazolyl, pyridazinyt, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, benzo-) WO 2010/083870 PCT/EP2009/009218 i -95- furanyl, isoindolyl, quinazolinyl, quinoxalinyl, pyrimidiny!, indazolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]- pyridinyl or 1,3-benzodioxolyl, ° and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.15. Compounds according to one or more of Claims 1-14 in which wo (>) denotes pyrrolidinyl, imidazolinyl, pyrazolyl, 2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, morpholinyl or N, Zz denotes imidazopyrimidinyl, triazolopyrimidinyl or pyrrolo- pyrimidinyl, where Z is bonded to a nitrogen of the radical D, Y denotes (CH), or is absent, X denotes O(CHy),, NH, NA, OC(=0), NHSQ; or is absent, =3 denotes H, A or COA, R? denotes H or NH, R denotes H, Ar or Het, oo Ar denotes phenyl, naphthyl or biphenyl, each of which is » 25 unsubstituted or mono-, di-, tri- tetra- or pentasubstituted by Hal, A, OR®, N(R%),, [C(R®)2],CN, (CH2)mCOOR® and/or CHoNH(CHz)q Het, Het denotes a mono- or bicyclic saturated, unsaturated or aro- matic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, (CH2)mOR®, (CH2)mN(R®)2, (CH2)mCN, (CH2)mCOORS, CONH(CH2),COOH, CONH(CHz)mHet?, CO(CH2)mN(R®),, CO(CH2)mNH(CH,),COOA, (CH2),CONH(CH2)mAr", COCH[(CH2)mCONH]NH,, COCH[(CH2)mCONH,INHCOOA,i - 96 - COCH[(CH2)mHet INHCOOA, COCH(NHCOA)CH,CONH;, (CH) NHCOOA, COCHI[(CH2)CNINHCOOA, COO{CH,)mCN, ; COO(CH2)mN(R®),, CO(CH2)mCON(R®),, COR®, COHet?, O(CHa)mAr" and/or =O (carbonyl oxygen), Het? denotes imidazolyl, indolyl, isoxazolyl, pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, benzo- furanyl, isoindolyl, quinazolinyl, quinoxalinyl, pyrimidinyi, indazolyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, pe tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]- pyridinyl or 1,3-benzodioxolyl, R® denotes H or alkyl having 1-6 C atoms, Ar’ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or SO;NH,, Hal denotes F, Cl, Br or |, m denotes 0,1, 2, 3,4, 50r6, n denotes 1 or 2, g denotes 0, 1, 2, 3 or 4, r denotes 0, 1 or 2, and pharmaceutically usable salts, tautomers and stereoisomers thereof, oo including mixtures thereof in all ratios. LS 2516. Compounds according to Claim 1, selected from the group Name and/or structureNo. "Al" 7-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]- ae "AZ" 5-[(R)-2-(Naphthalen-1-yloxymethylpyrrolidin-1-yi]- = LT een"A4" 2-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]- triazolo[4,3-a]pyrimidine - OD CONI. N~ "AS" 5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methoxy)quinoline { - "AB" 7-[2-(Naphthalen-1-yloxymethyl)imidazol-1-yljtriazolo- o | [1,5-a]pyrimidine "AR" N—-N" oN LA 4-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)quinoline "AQ" 0 F — No NY o—&F tL A 25 ¢ N = —0 E N=( ~ N= 4 \ N 4-((R)}-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)-6-trifluoromethoxyquinoline-08- "AQ" F F i» N ~ {op 0 N=( = N= / \ N 4-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)-6-trifluoromethylguinoline "AT" = | 1 =N LL ’ WN, N-4-Fluorobenzyi-4-((R)-1-[1,2 4]triazolo[1,5-a]pyrimidin-7- ylpyrrolidin-2-ylmethoxy)quinoline-2-carboxamide "AD" rr0 N N / OW N N = © No oo SN NC) " F N-[2-(4-Fluorophenylethyl]-4-((R)-1-[1,2,4]triazolo[1,5-a]- pyrimidin-7-ylpyrrolidin-2-ylmethoxy)quinoline-2- carboxamide"A113" » oO Le o NH N-Ethyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)quinoline-2-carboxamide "A14" N 1, po LI o Lo N—N~ = Lh 7-[2-(Naphthalen-1-yloxymethyl)imidazol-1-yl]-[1,2,4]- triazolo[1,5-a]pyrimidine "AR" Ce LA 5-[(R)-2-(Naphthalen-1-yloxymethylpyrrolidin-1-yl]- " imidazo[1,2-a]pyrimidine or 25 "A a" EY N._ = LA N 1-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-y!- methoxy)isoquinoline"A 7" = N N “0.0 Cr) PE 5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methoxy)isoquinoline "AA a8" 0 AN Se P H ~~ Od N | N==/ N-[3-(2-Oxopyrrolidin-1-yl)propyl]-4-((R)-1-[1,2,4]triazolo- [1,5-a]pyrimidin-7-ylpyrrolidin-2-ylmethoxy)quinoline-2- carboxamide "A ag" 0 o RNL J. O N™ N A oy - LAs N= Ethyl 5-methyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-1H-pyrazole-3-carboxyiate"A220"\ l.. 0 XL EY NT (Lo (2-Morpholin-4-ylethyl)-[4-((R)-1-[1,2,4]triazolo- [1,9-a]pyrimidin-7-ylpyrrolidin-2-ylmethoxy)naphthalen-1- ylmethyljamine Yd "ADT! OO) av, 1s Yo \ on { : N-— 4 )—N G Cd (3-Morpholin-4-ylpropyl)-[4-{(R)-1-[1,2,4]triazolo- [1,5-alpyrimidin-7-ylpyrrolidin-2-yimethoxy)naphthalen-1- ylmethyllamine "ADDY — 0 oe N C TH Cw CLC 0 rd OY Cr A N/ N-Benzyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yI- pyrrolidin-2-ylmethoxy}quinoline-2-carboxamide"A23Y¢ . 0 ; = N —0 H a Cv, My aN N-[2-(1H-Indol-3-yl)ethyl]-4-((R)-1-[1,2,4]triazolo- [1,5-a]pyrimidin-7-ylpyrrolidin-2-ylmethoxy)quinoline-2- carboxamide ¢ ; "A224" %, 4 Lo O an —_ N q \ © [ a aN N-[2-(4-Sulfamoylphenylethyl]-4-((R)-1-[1,2 4]triazolo- [1,5-a]pyrimidin-7-ylpyrrolidin-2-ylmethoxy)quinoline-2- carboxamide "A2R" Oy % N N— 0 : Se iveeti Le 25 N= N tert-Butyl 8-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yI- pyrrolidin-2-yimethoxy)-3,4-dihydro-1H-isoquinoline-2- carboxylate) WO 2010/083870 PCT/EP2009/009218 . - 103 - "A28" © N N—. ¢ 27 —0 — F v= lata(R)-1-[1,2,4]Triazolo[1,5-a}pyrimidin-7-ylpyrrolidin-2-yl- methyl 4-flucrobenzoate "ADT" OS N N— H ¢ ON 0 N N=( gn N= 8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yipyrrolidin-2-yl- methoxy)-1,2,3,4-tetrahydroisoquinoline 1 5 "ASK" 0 H = © : Cl ( np N= N N=" N-[2-(4-Chlorophenyl)ethyl]-4-((R)-1-[1,2,4]triazolo[1,5-a]- ¢ 5 pyrimidin-7-ylpyrrolidin-2-ylmethoxy)}quinoline-2-carbox- amide "AZ2Q" — HN O (> 0) N N— 0 ¢ ON *—Q Nn H 50 ~S o~&- N= tert-Butyl {(R)-1-carbamoylmethyl-2-ox0-2-[8-((R}-1-[1,2,4]- triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-ylmethoxy)-3,4- dihydro-1H-isoquinolin-2-yllethyllcarbamate i - 104 - "A300" i (J a ¢ > No NL ~ ACN N= © N-Ethylpropyl-4-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yi- pyrrolidin-2-yimethoxy)quinoline-2-carboxamide "AZM" w $Y 3 ¢ Sn 3 “go N Nd N= H 4 ( £7 N tert-Butyl {2-oxo0-2-[8-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin- 7-ylpyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinolin-2- yllethyl}carbamate "A3D" | 40. NH wh ; ¢ Sy- “nD N N=( NH, " (S)-3-Acetylamino-4-oxo-4-[8-((R)-1-[1,2 4]triazolo[1,5-a]- pyrimidin-7-ylpyrrolidin-2-ylmethoxy)-3,4-dihydro-1H- { - isoquinolin-2-yllbutyramide "TAZ33" © 0 N N— - ¢ TN “—Q N N=( 1-[8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yipyrrolidin-2- { ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yljethanone"A34" © o No NH 1 ¢ ON —Q N © N= N=[soxazol-5-yI-[8-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yl]- methanone "A3R" H N ® NO N— ¢ po ~~ 1 tert-Butyl {4-[8-((R)-1-[1,2 4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yi}- butyl}carbamate "A338" H,N OQ (> 0 J N N—, ¢ ON “—Q N NH, N=( y= (R)-3-Amino-4-oxo0-4-[8-((R)-1-[1,2 4]triazolo[1,5-a]- = 25 pyrimidin-7-ylpyrrolidin-2-ylmethoxy)-3,4-dihydro-1H- isoquinolin-2-yllbutyramide A37 oy o NN Py ¢ TN “em Q) N NH, =/ \ ” “ O N 2-Amino-1-[8-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yl]- ethanone"A38" a N * N=5-[8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2- ylmethoxy)-3,4-dihydro-1H-isoquinelin-2-yl]pentanenitrile "A3Q" fl 0 ( 0 a N Lo J o O v= wd 0 Tt tert-Butyl {(R)-2-cyano-1-[8-((R)-1-[1,2.4]triazolo- [1,5-alpyrimidin-7-ylpyrrolidin-2-ylmethoxy)-3,4-dihydro- 1H-isoquinoline-2-carbonyijethyl}carbamate "A400" v ™S ; Cn % - B eg So YO 4-Cyanobutyl 8-((R)-1-[1,2 4}triazolo[1,5-a]pyrimidin-7-yl- { 05 pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinoline-2- carboxylate "A411" N > NH, IN N { ~~ CD N= 4-[8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2- ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yl]butylamine) WO 2010/083870 PCT/EP2009/009218 - 107 - "A422" oS NH, N Nes 0 ¢ Sn : Po —Q N=( h N =4-Aminobutyl 8-((R)-1-[1,2 4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinocline-2- carboxylate "A43" ] N Lo LL, Pe 8 % Ney x . ¢ > (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yI- methyl 3-methoxybenzoate "A44" 0 SY = — NTN (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 3-bromobenzoate 05 "A45" N nO e Oo 7 Che (R)}-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yI- methyl 3-iodobenzoate) WO 2010/083870 PCT/EP2009/009218 -108 - "AAG" Cl Bi NE r 0 7 (=p (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methyl 2-chloroquinoline-4-carboxylate "AAT" 0 £ NT SNF 7-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1-y{]-1,2,5- thiadiazolo[3,4-b]pyridine "A48" { M0 N N~ ary F 7-[(R)-2-(3-Trifluoromethylbenzyloxymethyl)pyrrolidin-1-yl]- [1,2,4]triazolo[1,5-a]pyrimidine "A4Q"i. { M0(. 25 NT N- 29 N N= l 7-[(R)-2-(3-lodobenzyloxymethyhpyrrolidin-1-yl]-[1,2,4]- triazolo[1,5-ajpyrimidine) WO 2010/083870 PCT/EP2009/009218 -109 - "ARO" » wo NZS (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 3-dimethylaminobenzoate "AG" N Co IL N={( N { ~ N= . 7-[(R)-2-(3-Methoxybenzyloxymethyl)pyrrolidin-1-yl]- [1,2,4]triazolof1,5-a]pyrimidine 1 5 "ARDY N oo LL,N-. C J 9 CL | (R}-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 3-fluorobenzoate "AR3" o I a ¢ ON —Q N Lo 25 No 5 N O 9-0Ox0-5-[8-((R)-1-[1,2 4]triazoio[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinolin-2-yl}- pentanamide) WO 20106/683870 PCT/EP2009/009218 -110- "AR4™ {LL >, © N JON N~ ry N Nd 3-((R)-1-[1,2.4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxymethyl)benzonitrile "ARF" %. —N Na —0O zs 7-[(R)-2-(3-Fluorobenzyloxymethyl)pyrrolidin-1-yl-[1,2,4]- triazolo[1,5-alpyrimidine "ABB" [) o ~ N— \ ¢ TY =~ N= NC 7-[(R)-2-(Pyridin-3-yImethoxymethyi)pyrrolidin-1-yl]-[1,2,4]- triazolo[1,5-a]pyrimidine "ART" Cy 0 N- 7 N ~0 OHL. 25 INT yy N [2-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methoxy)phenyllacetic acid "ARE" [) 0 7 Ne \ NT = - ¢ 0 N N N= 7-[(R)-2-(Pyridin-4-yImethoxymethyl)pyrrolidin-1-yl}-[1,2,4]- triazolo[1,5-alpyrimidine} WO 2010/083870 PCT/EP2009/009218 - 111 - "ARQ" H(I. N N 0 N N= O Methyl 2-((R}-1-[1,2,4]triazolof1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethoxymethyl)-1H-indole-5-carboxylate "AB0" Ney, > 0 Fe ¢ - ho - (R)-1-[1,2,4]Triazolo[1,5-alpyrimidin-7-ylpyrrolidin-2-yl- methyl 3-trifluoromethylbenzoate "AB " Cl = L \ J. Lo JI AY © Ch (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 6-chloronicotinate "ABZ" = a N oo J“. 925 yD eh (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 2-phenoxynicatinate’ WO 2010/083870 PCT/EP2009/009218 -112 - "AB3" en N- oO 0 F NT ¢ 0 1 N™ nN (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 2-trifluoromethoxy benzoate "AR4" a —N N eo LCN. A J ee O oo N={_ _ o od N (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methyl 6-phenoxynicotinate "ABS" QQ p N N—. © ON =O J °N N=( \ _ N= Cl 7-[(R)-2-(2,6-Dichlcropyridin-4-yimethoxymethyl)pyrrolidin- 1-yl]-[1,2,4]triazolo{1,5-a]pyrimidine "ABB" 7-1(R)-2-(3-Bromobenzyloxymethyl)pyrrolidin-1-yi]-[1,2,4]- ee triazolo[1,5-a]pyrimidine L i: - To BN 25 "ABT" 7-[(R)-2-(3-Triflucromethoxybenzyloxymethyl)pyrrolidin-1- yll-[1,2,4]triazolo]1,5-a]pyrimidine "AGE" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 2-iodobenzoate "ABQ" (R)-1-[1,2,41Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl pyridine-2-carboxylate’ WO 2010/083870 PCT/EP2009/009218 i -113 - "ATO" = Hho LO No 0 NX ¢ ~ Ny? (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yI- methyl nicotinate "A711" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl benzoate "AT2" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- { methyl 3-ethoxybenzoate "A73" (R)-1-{1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-y}- methyl 5-chloro-2-flucrobenzoate"AT4" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 3-chloromethylbenzoate "ATH" oy %5 N N— 0 ZN “—Q N = BD Nw . 3-Aminopropyl 8-((R)-1-[1,2,4]triazolo[1,5-ajpyrimidin-7-yl- pyrrolidin-2-ylmethoxy)-3,4-dihydro-1H-isoquinoline-2- “ 25 carboxylate "ATR" © N N— ¢ ON —Q No Nn, N=( N= 3-[8-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2- ylmethoxy)-3,4-dihydro-1H-isogquinolin-2-ylJpropylamine "ATT" 7-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]- triazolo[1,5-a]-1,3,5-triazine’ WO 2010/083870 PCT/EP2009/009218 ) -114 - "AT78" (7) 0 NT __ N N= 0 N= 2-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methyl)isoindole-1,3-dione "ATTY" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl- methyl 3-cyanobenzoate i. "ABO" wo L \ J CS N- N™ w= TY OC TEN 7-[(R)-2-(Naphthalen-1-yloxymethyl)pyrrolidin-1-yl]-[1,2,4]- triazolo[1,5-a]pyrimidin-2-ylamine "AS1" O N ¢ Ny ry = \ = Ty Methyl 2-(1-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2- ro - ylmethyl)-1H-indole-5-carboxylate "A82" (R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yi- methyl 3-triflucromethoxy benzoate "AB3" LAL _OH ; Cr) N” NT ((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-ylpyrrolidin-2-yl)- methanolBN - 115 - "AB4" H { N be Mgr TL Cr) N" NT 4-Fluoro-N-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl- pyrrolidin-2-ylmethyhbenzenesulfonamide "ABH" \ § CN N= \ N= N - 2-Methyl-2-[4-([1,2 4]triazolo[1,5-a]pyrimidin-7-ylamino)- phenyl]propionitrile "ASK" 0 (ye N f © os, SSN 7-[2-(2-Ethoxyphenoxymethylmorpholin-4-yl]-[1,2,4]- triazolo[1,5-a]pyrimidine - "ABT" oo 87 No oY aS \ NN OH N~7 OH 4-(4-[1,2,4] Triazolo[1,5-a]pyrimidin-7-yImorpholin-2-yl)- benzene-1,2-diol} WO 2010/083870 PCT/EP2009/009218 . -116 - "ABS" y oN NN 7-(2-Oxa-b-azabicyclo[2.2.1Thept-5-yI)-[1,2,4]- triazolo] 1,5-a]pyrimidine ABI NE WARY YN IA N,N Co 7-Morpholin-4-yl-[1,2 4]triazolo[1,5-a]pyrimidine "AGO" NNN Oo a amt N uN 7-(2,6-Dimethylmorpholin-4-yi)-[1,2 4]triazolo- [1,5-alpyrimidine "AO 1 Ves N \ Ny / N 0HN. _~ { 25 : 4-Morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine "AQ2" 0 ~~ N ¢ NA I N=( N N N-{4-(Cyanodimethylmethyl)phenyl]-N-[1,2 4]triazolo- [1,5-a]pyrimidin-7-ylacetamide"AQ3" AN \ N_/ (7° N N— 0 Th R= Mg \ H N—7 tert-Butyl ((R)-1-(1H-imidazol-4-ylmethyl)-2-oxo-2-{8-[(R)- 1-(9H-purin-6-yhpyrrolidin-2-ylmethoxy}-3,4-dihydro-1H- isoquinolin-2-yl}ethyl)carbamate and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.17. Process for the preparation of compounds of the formula | according to Claims 1-16 and pharmaceutically usable salts, tautomers and stereo- isomers thereof, characterised in that a compound of the formula ll : 1 Y-X-R R £27 I H in which R', X. Y and R have the meanings indicated in Claim 1, is reacted with a compound of the formula Ili Z-Cl I in which Z has the meaning indicated in Claim 1,: WO 2010/083870 PCT/EP2009/009218 ) -119 - ment for the treatment of tumours, where a therapeutically effective amount of a compound of the formula | is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic ° agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse tran- scriptase inhibitor and 10) further angiogenesis inhibitors.22. Use of compounds of the formula | according to Claim 1-18 and/or ~~ physiologically acceptable salts thereof for the preparation of a medica- ment for the treatment of tumours where a therapeutically effective amount of a compound of the formula | is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modula- tor, 4) cytotoxic agent, 5) antiproliferative agent, 8) prenyl-protein trans- ferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibi- tor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibi- tors. of 25
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009005193A DE102009005193A1 (en) | 2009-01-20 | 2009-01-20 | Novel heterocyclic compounds as MetAP-2 inhibitors |
PCT/EP2009/009218 WO2010083870A1 (en) | 2009-01-20 | 2009-12-22 | Novel heterocyclic compounds for use as metap-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG174118A1 true SG174118A1 (en) | 2011-10-28 |
Family
ID=42210278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011050564A SG174118A1 (en) | 2009-01-20 | 2009-12-22 | Novel heterocyclic compounds for use as metap-2 inhibitors |
Country Status (16)
Country | Link |
---|---|
US (1) | US8546406B2 (en) |
EP (1) | EP2379558B1 (en) |
JP (1) | JP5619025B2 (en) |
KR (1) | KR20110112434A (en) |
CN (1) | CN102292339B (en) |
AR (1) | AR075035A1 (en) |
AU (1) | AU2009337953B2 (en) |
BR (1) | BRPI0924033A2 (en) |
CA (1) | CA2749970C (en) |
DE (1) | DE102009005193A1 (en) |
EA (1) | EA201101090A1 (en) |
ES (1) | ES2575687T3 (en) |
IL (1) | IL213935A (en) |
MX (1) | MX2011007641A (en) |
SG (1) | SG174118A1 (en) |
WO (1) | WO2010083870A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008027574A1 (en) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | New pyrrolidine derivatives as MetAP-2 inhibitors |
ES2934986T3 (en) * | 2019-01-22 | 2023-02-28 | Merck Patent Gmbh | heterocyclic derivatives |
WO2023196540A1 (en) * | 2022-04-06 | 2023-10-12 | Vanderbilt University | Articles and methods for inhibiting methionine aminopeptidase activity |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037980A (en) * | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
FR2448542A1 (en) * | 1979-02-06 | 1980-09-05 | Landerlan Sa Lab | 7-Amino 1,2,4-triazolo 2,3-A pyrimidine(s) - are coronary vasodilators, hypoglycemics and anaphylaxis inhibitors |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
MX9709867A (en) * | 1995-06-07 | 1998-03-31 | Pfizer | Heterocyclic ring-fused pyrimidine derivatives. |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
PA8474101A1 (en) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
PE20011222A1 (en) | 2000-04-14 | 2001-12-07 | Abbott Lab | HYDRAZIDES AND ALCOXYAMIDES INHIBITING ANGIOGENESIS |
US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
WO2002081415A2 (en) | 2001-04-03 | 2002-10-17 | Smithkline Beecham Corporation | Method for inhibiting metap2 |
JP4306206B2 (en) * | 2001-09-04 | 2009-07-29 | 住友化学株式会社 | Imidazo [1,2-a] pyrimidine, its use and production intermediate |
US20070275961A1 (en) * | 2003-06-04 | 2007-11-29 | Vernalis (Cambridge) Limited. | Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine |
CN1933844A (en) * | 2003-12-22 | 2007-03-21 | 吉里德科学公司 | Phosphonate compounds having immuno-modulatory activity |
US20050187389A1 (en) * | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
TW200613306A (en) * | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
BRPI0608513A2 (en) * | 2005-03-15 | 2010-01-05 | Irm Llc | compounds and compositions as protein kinase inhibitors |
DE102005037733A1 (en) | 2005-08-10 | 2007-02-15 | Merck Patent Gmbh | adenine |
WO2008012635A2 (en) * | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
DE102008027574A1 (en) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | New pyrrolidine derivatives as MetAP-2 inhibitors |
-
2009
- 2009-01-20 DE DE102009005193A patent/DE102009005193A1/en not_active Withdrawn
- 2009-12-22 EA EA201101090A patent/EA201101090A1/en unknown
- 2009-12-22 WO PCT/EP2009/009218 patent/WO2010083870A1/en active Application Filing
- 2009-12-22 CA CA2749970A patent/CA2749970C/en active Active
- 2009-12-22 BR BRPI0924033A patent/BRPI0924033A2/en not_active Application Discontinuation
- 2009-12-22 MX MX2011007641A patent/MX2011007641A/en not_active Application Discontinuation
- 2009-12-22 SG SG2011050564A patent/SG174118A1/en unknown
- 2009-12-22 JP JP2011546612A patent/JP5619025B2/en active Active
- 2009-12-22 EP EP09796971.1A patent/EP2379558B1/en active Active
- 2009-12-22 AU AU2009337953A patent/AU2009337953B2/en active Active
- 2009-12-22 ES ES09796971.1T patent/ES2575687T3/en active Active
- 2009-12-22 KR KR1020117019386A patent/KR20110112434A/en not_active Application Discontinuation
- 2009-12-22 CN CN200980154939.0A patent/CN102292339B/en active Active
- 2009-12-22 US US13/145,422 patent/US8546406B2/en active Active
-
2010
- 2010-01-20 AR ARP100100121A patent/AR075035A1/en unknown
-
2011
- 2011-07-05 IL IL213935A patent/IL213935A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BRPI0924033A2 (en) | 2016-01-26 |
WO2010083870A1 (en) | 2010-07-29 |
CN102292339A (en) | 2011-12-21 |
US20110281859A1 (en) | 2011-11-17 |
CA2749970A1 (en) | 2010-07-29 |
CN102292339B (en) | 2015-01-28 |
IL213935A0 (en) | 2011-07-31 |
IL213935A (en) | 2017-06-29 |
AU2009337953B2 (en) | 2016-02-11 |
JP2012515731A (en) | 2012-07-12 |
AR075035A1 (en) | 2011-03-02 |
EP2379558B1 (en) | 2016-03-23 |
MX2011007641A (en) | 2011-09-06 |
ES2575687T3 (en) | 2016-06-30 |
KR20110112434A (en) | 2011-10-12 |
EP2379558A1 (en) | 2011-10-26 |
EA201101090A1 (en) | 2012-03-30 |
JP5619025B2 (en) | 2014-11-05 |
CA2749970C (en) | 2017-11-28 |
US8546406B2 (en) | 2013-10-01 |
DE102009005193A1 (en) | 2010-07-22 |
AU2009337953A1 (en) | 2011-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2727282C (en) | Pyrrolidine derivatives as metap-2 inhibitors | |
AU2012213775B2 (en) | 7-Azaindole derivatives | |
CA2760844C (en) | 3-(1,2,3-triazol-4-yl)pyrrolo[2,3-b]pyridine derivatives | |
CA2691223C (en) | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids | |
CA2816363C (en) | 7-(1,2,3-triazol-4-yl)pyrrolo[2,3-b]pyrazine derivatives | |
IL234953A (en) | Cyclic amide derivatives, their preparation and pharmaceutical compositions containing them | |
CA2824293C (en) | 5-(1,2,3-triazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine derivatives | |
CA2712612A1 (en) | 4-(pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-ylamine derivatives | |
WO2012072200A1 (en) | 3-hetaryl-substituted pyrrolo[2,3-b]pyridine derivatives as pdk1 inhibitors | |
CA2749970C (en) | Heterocyclic compounds as metap-2 inhibitors |